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Chronic hepatitis can present a diagnostic challenge, with different types of chronic 
hepatic disease being associated with similar clinical and laboratory findings. Clinical 
signs of chronic hepatitis are often non-specific; therefore, this disease is frequently 
diagnosed in an advanced stage that makes successful intervention less likely. 
Differentiating dogs with chronic hepatitis from those with acquired hepatopathies is often 
difficult requiring invasive diagnostic procedures such as laparoscopic liver biopsy. There 
is also a need for biological markers that are able to stage chronic hepatitis non-invasively. 
Currently, the only way to establish a definitive diagnosis of chronic hepatitis in dogs is 
through the histopathological assessment of a liver biopsy specimen. The acquisition of a 
liver biopsy specimen, although considered the gold standard, is invasive and has 
limitations and risks. The identification of biomarkers that are differentially expressed in 
dogs with chronic hepatitis could contribute to the development of novel diagnostic tests 
for this disease and provide insight into its pathogenesis. The objective of these studies 
was to identify candidate biomarkers that are differentially expressed in the liver, serum, 
or urine of dogs with chronic hepatitis. The hepatic proteome, serum and urine 
metabolome, and hepatic microRNA transcriptome were analyzed by 2-dimensional 
fluorescence difference gel electrophoresis coupled to nanoflow liquid chromatography 
tandem mass spectrometry, gas chromatography – quadrupole time of flight mass 
spectrometry, and high-throughput small RNA Illumina sequencing, respectively. 
Differential hepatic protein expression of cytokeratin 18 and annexin 5 was demonstrated 




ratio of branched chain amino acids to aromatic amino acids in the serum of dogs with a 
congenital portosystemic shunt. The assessment of serum trans-4-hydroxyl-proline 
confirmed a decreased concentration in dogs with chronic hepatitis. Untargeted 
metabolomic profiling of urine in dogs with chronic liver disease documented alterations 
in metabolites involved in glutathione, arginine, proline, and nitrogen metabolism in 
addition to metabolites involved in fatty acid biosynthesis. Differential microRNA 
expression of transcripts implicated in hepatic fibrosis and apoptosis was demonstrated in 
dogs with chronic hepatitis. Further targeted assessment of the novel biomarkers identified 
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My mother always said I am no one. I am no body. She did not recognize the profound 
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%CV  Coefficient of variation 
DQC  Dilution quality control 
LC-MS-MS  Liquid chromatography–tandem mass spectrometry 
LLOQ  Lower limit of quantification  
PVDF  Polyvinylidene difluoride 
TTBS  Tween - Tris buffered saline 
ALT   Alanine aminotransferase 
ALP   Alkaline phosphatase 
GGT   Gamma-glutamyl transferase 
DIGE  Difference gel electrophoresis 
MWM   Molecular weight marker 
kDA   Kilodalton 
NL   Nonlinear 
CK18   Cytokeratin 18 
ANX5   Annexin 5 
AAA  Aromatic amino acids 
BCAA  Branched chain amino acids 
HMGB1  High mobility group box-1 
GSTα  Alpha glutathione-S-transferase 
TGF-β1  Transforming growth factor beta-1 




MMP  Matrix metalloproteinase 
2-DE  2-dimensional gel electrophoresis 
miRNA  MicroRNA 
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1. INTRODUCTION AND LITERATURE REVIEW 
 
 Canine chronic hepatitis 
Chronic hepatitis is the most common type of liver disease in dogs with idiopathic chronic 
hepatitis being the most frequently observed form [1]. Chronic hepatitis is associated with 
hepatocellular damage resulting in an aberrant repair process that can lead to end-stage 
liver disease characterized by fibrosis of the liver and the replacement of normal liver 
architecture into abnormal regenerative liver nodules with portal – central vascular 
anastomoses [2]. End-stage hepatic disease, determined histologically, carries a poor long 
term prognosis with a reported 0.4 month survival time [3,4]. In contrast, chronic hepatitis 
diagnosed prior to the development of ascites and cirrhosis carries a reported survival from 
diagnosis to death of 18.3 – 36.4 months [3,4]. Cases of chronic hepatitis are often 
diagnosed in an advanced stage where treatment is less likely to be effective and thus early 
identification of dogs with chronic hepatitis before clinical signs develop is crucial. The 
lack of robust biomarkers for canine chronic hepatitis limits the non-invasive evaluation 
of this disease. The histological assessment of a liver biopsy specimen continues to be the 
gold standard for the assessment of hepatocellular necrosis, inflammation, and fibrosis, as 
well as providing a histomorphological diagnosis. Liver biopsies however, are not without 
risk or limitations and are often indicated for patients with a compromised health status. 
Risks inherent to liver biopsy include hypotension, hemorrhage, and collateral damage to 
adjacent organs [41]. Patients with suspected chronic hepatitis can also have ascites, 
coagulopathies, or thrombocytopenia and at increased risk of complications secondary to 





rendering evaluation of a relatively small liver biopsy specimen susceptible to sampling 
bias [42]. Furthermore, repeated biopsies to evaluate disease progression or treatment 
response are impractical due to the increased risk of complications and financial burden. 
Novel non-invasive biomarkers are therefore, needed to stage, monitor, and diagnose 
chronic hepatitis. 
 
A number of non-invasive biomarkers of hepatocellular injury have been identified and 
validated. The most widely used biomarker of hepatocellular injury is serum alanine 
aminotransferase (ALT) activity with an increased serum ALT activity being considered 
the gold standard for detection of hepatocellular injury [5,6]. Alanine aminotransferase is 
predominantly found in the liver with lower enzyme activities found in skeletal and 
cardiac muscle. Serum enzyme activity increases are associated with either reversible or 
irreversible hepatocellular damage [7]. Serum alanine aminotransferase activity has a 
reported sensitivity for detecting liver disease in symptomatic dogs that varies from 60% 
– 76% [8]. There is little known about the sensitivity of biomarkers including that of 
alanine aminotransferase, to detect hepatocellular injury in patients with subclinical 
disease. A study by Dirksen et al. reported sensitivities of alanine aminotransferase, 
alkaline phosphatase, and bile acids for identifying subclinical chronic hepatitis of 71%, 
35%, and 13% respectively [9]. Alanine aminotransferase, although considered sensitive 
for the detection of hepatocellular injury does not indicate when the injury occurred in 
terms of determining drug or toxin exposure. Also, alanine aminotransferase activity is 
inducible with drug therapy and thus even marked serum elevations may result from 





aminotransferase activity does not always correlate with clinical data, which makes 
interpreting disease severity difficult.   
 
There are several candidate biomarkers of hepatocellular injury in the human literature 
that have demonstrated increased sensitivity and specificity when compared to alanine 
aminotransferase. MicroRNAs are a class of small noncoding RNA that regulates post-
transcriptional gene expression. Various studies have demonstrated the ability of 
microRNAs of hepatic origin to function as stable and sensitive non-invasive biomarkers 
of hepatocellular injury in animal models and in human patients with normal or increased 
serum ALT concentrations. Several studies have indicated that hepatocyte-derived 
microRNAs may have a higher sensitivity than serum ALT for hepatocellular injury [10-
12]. A recent study in Labrador Retrievers found microRNA-122 to be highly sensitive 
and specific for the detection of hepatocellular injury with the ability to identify more 
patients with hepatocellular injury than ALT activity [13]. MicroRNA-122 was also able 
to identify patients with high hepatic copper contents but normal ALT activity [13]. 
MicroRNA-122 is the only biomarker of hepatocellular injury that has been found to be 
more sensitive than alanine aminotransferase in the veterinary literature.  
 
Cytokeratin 18 (CK18) is an intermediate filament protein expressed in hepatocytes [14]. 
The cleavage of CK18, mediated by caspase, occurs during the structural cellular 
rearrangement of apoptosis [14]. Passive release of full-length cytokeratin 18 occurs in 
cellular necrosis where the release of cytokeratin 18 fragments occurs in apoptosis [15]. 





(suggestive of apoptosis) and or full-length cytokeratin 18 (suggestive of necrosis). These 
markers have been evaluated for the monitoring of chemotherapeutic drugs and the 
assessment of apoptosis in patients with chronic hepatic diseases in humans [16]. 
Elevations in the serum concentrations of cytokeratin 18 in individuals with acute hepatic 
disease was associated with a poorer prognosis and CK18 was increased in some patients 
with serum ALT activity within the reference interval [16].  
 
Glutamate dehydrogenase is an enzyme found in the mitochondria of hepatocytes with 
small amounts in the kidney and the central nervous system; however, serum activity 
originates almost exclusively from the liver [5]. Glutamate dehydrogenase is conserved 
across many species, which makes it a good candidate biomarker. An experiment in rats 
exposed to methapyrilene, dexamethasone, cyproterone, isoniazid, and lead nitrate 
showed that glutamate dehydrogenase elevations were of greater magnitude and lasted 
longer than those of alanine aminotransferase [17]. This study concluded that glutamate 
dehydrogenase was more specific and less inducible than alanine aminotransferase. An 
inducible enzyme, active during the second phase of hepatic detoxification, known as  
glutathione-s-transferase catalyzes the conjugation of glutathione with metabolites that 
were formed during phase one of detoxification [16]. There are four isozymes of 
glutathione-s-transferase (i.e.alpha, pi, mu, and theta) expressed in humans and 
mammalian species [16]. The alpha glutathione-s-transferase (GST) class is of particular 
interest because it is expressed in hepatocytes. Rats administered hepatotoxins to cause 
hepatocellular damage demonstrated serum GSTα concentrations that correlated with 





informative regarding prognosis or disease severity [18]. A case report of patients with 
self-induced acetaminophen toxicity all developed increased serum glutathione-S-
transferase alpha activities; however, alanine aminotransferase activities were within the 
reference interval in affected individuals up to 6 hours after intoxication [5].   
 
A protein released passively by necrotic cells called high mobility group box-1 (HMGB1) 
is able to activate the immune system by binding Toll-like receptors [16]. This protein has 
been used to indicate cellular death in studies of drug toxicity when measured in the serum. 
Serum levels of HMGB1 and the modified form acetyl-HMGB1 have been correlated with 
histopathologic assessment of hepatocellular inflammation and necrosis [16]. 
Furthermore, circulating HMGB1 concentrations are associated with circulating alanine 
aminotransferase concentrations in drug-induced acute hepatocellular damage and 
elevations of acetyl-HMGB1 were associated with a worse prognosis [16].  
 
Argininosuccinate synthetase is an important enzyme for the synthesis of arginine and is 
a critical enzyme in several metabolic processes that require arginine. Argininosuccinate 
synthetase has been shown to increase earlier and decrease faster than alanine 
aminotransferase in rodent models of liver injury caused by ischemia-reperfusion and by 
galactosamine-induced sensitization to endotoxin and these results were similar in human 
acetaminophen overdose patients [19]. Argininosuccinate synthetase levels were 
increased in serum after treatment with endotoxin alone while aminotransferase activities 





hepatocellular damage [19]. Argininosuccinate synthetase also appears to demonstrate a 
greater diagnostic range than alanine aminotransferase with greater maximum elevations.   
 
There are few biomarkers of hepatic fibrosis that have been assessed in the veterinary 
literature but several biomarkers of fibrosis that have been assessed in the human with 
hepatic disease. The identification of the stellate cell in the liver as the major source of 
extracellular matrix deposition has led to the identification of several molecules that result 
in the activation of hepatic stellate cells and fibrogenesis. Serum and urinary biomarkers 
of hepatic fibrosis can be divided into two groups. There are biomarkers of hepatic fibrosis 
that indicate altered liver function but are not correlated with the deposition of 
extracellular matrix (e.g. serum transaminase activities) called indirect biomarkers [20]. 
These indirect markers of hepatic fibrosis are utilized most often for the diagnosis of end 
stage liver disease or cirrhosis [20]. Direct markers of hepatic fibrosis reflect extracellular 
matrix (ECM) turnover and play roles in the non-invasive staging of liver disease [20]. 
Hyaluronic acid is a nonsulfated glycosaminoglycan distributed in connective tissue and 
is a chief component of the ECM. Hyaluronic acid has been evaluated as a serologic 
biomarker for hepatic fibrosis and has a reported sensitivity of 70% to 80% for 
differentiating mild fibrosis from  moderate to severe fibrosis and a specificity of 75% to 
100% [21]. Preliminary research indicates the measurement of circulating hyaluronic acid 
may have a role in the assessment of hepatic fibrosis in dogs. A study of chronic hepatitis 
in dogs found that those with end-stage hepatic fibrosis had higher circulating hyaluronic 
acid concentrations healthy control dogs, dogs with extra-hepatic disease, and dogs with 





A cytokine, hypothesized to have a role in fibrosis, is transforming growth factor beta-1 
(TGF-β1). Some of the functions of TGF-β1 include inhibition of cell division, inhibition 
of neoplastic cells, and suppression of the immune system; however, TGF-β1 causes 
apoptosis and fibrosis in the liver [22]. TGF-β1 has been investigated as a biomarker of 
liver fibrosis in dogs by measuring circulating TGF-β1 in healthy control dogs and in dogs 
with liver disease. Circulating TGF-β1 concentrations in the dogs with marked hepatic 
fibrosis was significantly different (P < 0.001) from concentrations in healthy control dogs 
[23]. This suggests a possible role for this cytokine in the assessment of hepatic fibrosis 
in dogs. 
 
The FibroVet test, released by Echosens is an index that evaluates various biological 
markers that are combined to form an index of hepatic fibrosis. A research abstract 
reported a study of this index to have the ability to differentiate dogs with hepatic fibrosis 
from those without fibrosis with an accuracy of 90% to 100%.  
 
There are several indirect and direct biomarkers for the assessment of hepatic fibrosis in 
the human literature. The indirect biomarkers that have been evaluated include serum 
activities of  alanine aminotransferase, the ratio of serum aspartate and alanine 
aminotransferase activities, platelet count, and prothrombin index [20].  Additional 
fibrosis indices include the combination of prothrombin time, serum gamma glutamyl 
transferase activity, and blood apolipoprotein A1 concentration to form the PGA index 
[20]. The PGA index with the inclusion of serum α2-macroglobulin concentration results 





fibrosis assessed in humans are characterized by their molecular structure and include 
collagens, glycoproteins, polysaccharides, collagenases, and cytokines [20]. Examples of 
collagens assessed in humans include pro-collagen one and three, which are pro-peptides 
released into the serum during ECM formation and type four collagen released during 
ECM degradation. Glycoproteins and polysaccharides that have been assessed include 
hyaluronic acid, tenascin, and laminin that have been identified in regions of matrix 
deposition. Collagenases and their inhibitors include the metalloproteinases and the tissue 
inhibitors of metalloproteinase. Cytokines that have been examined include TGF-β, which 
is involved in liver fibrosis. A study by Oberti et al. evaluated candidate biomarkers of 
hepatic fibrosis (i.e., PIIINP, hyaluronic acid, laminin, and TGF-β) in 243 human patients 
with chronic viral hepatitis and found that hyaluronic acid, PIIINP, laminin, and TGF-β 
achieved diagnostic accuracies of 86%, 74%, 81%, and 67%, respectively [24]. 
Circulating concentrations of tissue inhibitor of metalloproteinase (TIMP)-1 and matrix 
metalloproteinase (MMP)-2 have also been evaluated as biomarkers of hepatic fibrosis in 
chronic liver disease. A study by Boeker et al. found the ability of circulating MMP-2 to 
detect hepatic fibrosis was unacceptable with a sensitivity and diagnostic accuracy of 7% 
and 58%, respectively [25]. Circulating MMP-2 was able to predict end-stage liver disease 
with a sensitivity and specificity of 83% and 100%, respectively [25]. Similarly, 
circulating TIMP-1 concentrations were able to identify hepatic fibrosis with a sensitivity 
and specificity of 67% and 88%, respectively [25]. Furthermore, circulating TIMP-1 
concentrations were able to identify patients with end-stage liver disease with a sensitivity 





TIMP-1 for hepatic fibrosis was not significantly different than hyaluronic acid but 
superior to serum transaminase activity and serum albumin [25].  
 
In summary, there is a lack of clinically applicable non- invasive biomarkers for the 
detection of hepatocellular damage and hepatic fibrosis that drives biomarker discovery 
research in veterinary medicine in general and in canine chronic hepatitis more 
specifically. 
 Biomarker discovery 
A biological marker (biomarker) is defined by the Biomarkers Definitions Working Group 
as a parameter that can be objectively measured as an indicator of a normal biological 
process, pathogenic process, or a pharmacologic response to a therapeutic intervention 
[26]. Biomarkers have important roles in disease detection and in the monitoring of overall 
health status. The discovery of novel biomarkers using classes of -omics data has become 
an important objective in academic and commercial research. This is driven in part by the 
potential of biomarkers to serve as a surrogate for specific disease states while permitting 
a more comprehensive understanding of biology in health and disease. Biomarker research 
is composed of three phases: discovery (i.e., the quantitative identification of biomarker 
candidates), verification (i.e., the screening of candidates to identify the most promising 
candidates), and validation (i.e., the analytical and clinical evaluation of candidate 
biomarkers in a large diverse patient cohort). The discovery of biomarkers is based on the 
principle that the comparison of physiological states, phenotypes or changes across control 
and disease patient groups can identify differences in the abundance of molecules that can 





chronic hepatitis including inflammation, oxidative stress, apoptosis, and fibrosis. 
Potential biomarkers for each of these mechanisms are therefore of interest. 
 Proteomic analysis for biomarker discovery 
The recent advances in genomics research and mass spectroscopic technology has 
contributed to the development of the field of proteomics. The proteome encompasses the 
entire protein complement expressed by a genome and proteomics is the study of this 
protein complement. Proteomics is further defined as the global identification, 
characterization, and quantification of the proteins present in a biological sample or 
organism in specified conditions and is an effective technique for biomarker discovery 
[28]. There are several available proteomic platforms; however, the most commonly used 
platform is 2‐dimensional gel electrophoresis (2‐DE). The proteome is extracted from a 
biological sample and then separated according to their isoelectric points and their 
molecular weights to generate protein profiles in 2-DE. Typically, mass spectrometry is 
then utilized to produce mass spectra that is then compared to a library for identification 
of proteins in differentially expressed protein spots. During the development of disease 
proteins are altered or modified and these altered proteins can be detected in tissue, blood, 
urine, or other body fluids. Chronic inflammatory hepatobiliary disease has been 
demonstrated to result in changes to proteins found in hepatic tissues in humans [29]. 
There is a single proteomic study related to canine liver disease that has been published to 
date [30]. This study examined soluble proteome of the liver from 3 Bull Terriers (2 
diseased, 1 control) with inherited lethal acrodermatitis and identified differentially 
expressed proteins [30]. The proteomic analysis of hepatic tissue from dogs with chronic 





knowledge, prior to the one presented in this dissertation, there are no published studies 
on the hepatic proteome of dogs with chronic hepatitis. 
 Metabolomic analysis for biomarker discovery 
Metabolomics, the systematic study of small molecular weight molecules in cells, tissues 
or whole organisms, has been used in biomarker discovery for a range of diseases [31]. 
The analytical platforms used, includes nuclear magnetic resonance and mass 
spectrometry, and can characterize thousands of metabolites simultaneously. The power 
of metabolomics results from its ability to detect small alterations in metabolites that may 
precede a gross alteration in phenotype. Metabolomic studies can be classified as targeted 
or untargeted based upon when metabolites are identified. An untargeted metabolomic 
study is used for global analysis of all detectable analytes in a sample including the 
annotation of known and unknown analytes through database searches [32]. This approach 
is suited to biomarker discovery. A targeted metabolomic study employs tandem mass 
spectrometry or gas chromatography–mass spectrometry selected ion recording to 
determine precise and accurate relative abundances and concentrations of a known 
metabolite [32]. This approach is suited to validation and verification of a known 
metabolite. The application of metabolomics in veterinary medicine to detect global 
changes of populations of endogenous low molecular weight metabolites in biological 
samples in dogs with chronic hepatitis may allow the identification of surrogate disease 
profiles. A couple metabolomic studies have already been performed in veterinary 
medicine to characterize the changes in the metabolome that occur in hepatobiliary 
disease. Gookin et al. recently performed an untargeted metabolomic analysis of the serum 





compounds that were able to differentiate between healthy dogs and dogs with a 
gallbladder mucocele [33]. Another veterinary study employed a metabolomic strategy to 
evaluate the plasma metabolome of dogs with a congenital portosystemic shunt and dogs 
with acquired hepatic disease and detected alterations in the plasma bile acid and 
phospholipid profiles of dogs with a congenital portosystemic shunt [34]. The 
comprehensive analysis utilized in the metabolomic research platform can offer a more 
sensitive means of detecting small molecular alterations related to canine hepatobiliary 
disease. 
 MicroRNA transcriptomics for biomarker discovery 
MicroRNAs(miRNAs) are a class of small noncoding RNAs that are important regulators 
of posttranscriptional gene expression [35]. The miRNA transcriptome is the complete 
repertoire of miRNA in a cell or organism. The miRNA transcriptome reflects the miRNA 
transcripts that are being expressed at a given moment. Comparison of transcriptomes 
between experimental groups allows the identification of genes that are differentially 
expressed in distinct sample populations, disease states, or in response to different 
treatments. Transcriptomics is a high throughput technology enabling the relative 
quantification of expression of thousands of gene transcripts and with sequencing 
platforms, it is possible to assess the entire complement of transcripts within a cell or 
tissue. There are several platforms available to characterize and quantify the miRNA 
transcriptome, that include hybridization-based or sequence-based approaches. The 
hybridization-based approach usually involves the incubation of fluorescently labelled 
complementary DNA (cDNA) with customized microarrays. A sequence-based approach 





technology provides the platform for mapping and quantification of the miRNA 
transcriptome. Briefly, a sample of miRNA is reverse transcribed into a cDNA fragment 
library. Each cDNA fragment is then sequenced to obtain short reads. Following 
sequencing, the short reads are then aligned to a reference genome to construct a 
transcription map consisting of the transcript identity and level of expression for each 
transcript.  
 
MiRNAs are emerging as promising candidate biomarkers for a number of biliary and 
hepatic diseases in humans [36,37]. In human patients, several hepatocyte‐derived 
miRNAs, such as miR-122, miR-21, and miR-22, have been demonstrated to be sensitive 
biomarkers for acute or chronic liver damage caused by various forms of liver injury 
[12,38]. Other studies have also demonstrated different serum concentrations of miRNAs: 
miR-21, miR-31, miR-122, miR-145, miR-146a in human patients with hepatocellular 
carcinoma or intrahepatic cholangiocarcinoma [39,40]. There are only a few targeted 
transcriptomic studies in dogs with chronic liver disease. Dirksen et al. have analyzed the 
serum of dogs with various hepatobiliary diseases including chronic hepatitis for the 
presence of specific miRNA biomarkers identified in previous human studies [5,6,9,25]. 
These studies found circulating miR-122 and miR-148a values were elevated in the serum 
of Labradors with liver injury, and miR-122 values increased more markedly than those 
in the control group. Other findings included the ability to differentiate between 
parenchymal, biliary, and neoplastic hepatobiliary diseases with a miRNA panel 
consisting of miR-21, miR-122, miR-126, miR-200c, and miR-222. Transcriptomics 





development, and this has been demonstrated in comparative human studies. There are no 
published studies of untargeted transcriptomic studies of liver tissue in dogs with chronic 
hepatitis to the authors’ knowledge. 
 
The overall hypothesis of the studies presented here is that there is a difference of the 
hepatic proteome, serum and urine metabolome, and hepatic microRNA transcriptome 
between healthy dogs and dogs with chronic hepatitis. Experiments will allow 
identification of potential biomarkers that hold power for the differentiation of dogs with 
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2. PROTEOMIC ANALYSIS OF LIVER TISSUE FROM DOGS WITH CHRONIC 
HEPATITIS* 
 
Chronic hepatitis is the most common hepatic disease in dogs. Copper accumulation is an 
important cause of chronic hepatitis in dogs however; the etiology in most dogs cannot be 
determined. Clinical signs of chronic hepatitis are often non-specific; therefore, this 
disease is frequently diagnosed in an advanced stage that makes successful intervention 
less likely. Early diagnosis of chronic hepatitis in dogs would thus be beneficial. The 
identification of proteins that are differentially expressed in dogs with chronic hepatitis 
could contribute to the development of novel diagnostic markers for this disease and 
provide insight into its pathogenesis. The objective of this study was to identify novel 
proteins that are differentially expressed in the liver of dogs with chronic hepatitis. Hepatic 
tissue was collected from 8 healthy dogs during ovariohysterectomy and from 8 dogs with 
histologically confirmed chronic hepatitis. The proteome of the liver samples was 
extracted by mechanical disruption and detergent-based cell lysis and differentially 
labeled prior to analysis by 2-dimensional fluorescence difference gel electrophoresis. 
Spots with an absolute fold change value > 2.0 were selected for further analysis. Protein 
identification was achieved by nanoflow liquid chromatography tandem mass 
spectrometry. Differential expression of select proteins was validated by Western blot. 
                                               
* Reprinted with permission from Lawrence YA, Dangott LJ, Rodrigues-Hoffmann A, Steiner JM, 
Suchodolski JS, Lidbury JA (2018) Proteomic analysis of liver tissue from dogs with chronic hepatitis. PLoS 
ONE 13(11): e0208394. Copyright 2018 Lawrence et al. This is an open access article distributed under the 
terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and 





Five protein spots were differentially expressed between patients with chronic hepatitis 
and healthy control dogs. From these 5 protein spots 11 proteins were identified. 
Differential expression of cytokeratin 18 and annexin 5 were confirmed by Western blot 
analysis. Differential protein expression was shown between dogs with chronic hepatitis 
and healthy control dogs. Upregulation of cytokeratin 18 in chronic hepatitis may suggest 
increased hepatocellular apoptosis and necrosis, whereas upregulation of annexin 5A 
suggests increased hepatocellular apoptosis. Further studies are needed to determine 
whether either protein has diagnostic utility. 
 Introduction 
Chronic hepatitis is the most common type of liver disease in dogs with chronic hepatitis 
being the most frequently observed form [1]. Chronic hepatitis is associated with 
apoptosis/necrosis and an inflammatory infiltrate that is often mononuclear. This results 
in a repair process that can lead to hepatic fibrosis including end-stage liver disease 
characterized by fibrosis of the liver and the conversion of normal liver architecture into 
abnormal liver nodules with portal-central vascular anastomoses [2]. End-stage hepatic 
disease carries a poor long-term prognosis with a reported median survival time of 0.4 
months [3,4]. Chronic hepatitis, in contrast diagnosed at an earlier stage carries a reported 
median survival from diagnosis to death of 18.3 – 36.4 months [3,4]. Cases of chronic 
hepatitis are often diagnosed at an advanced stage where treatment is less likely to be 
effective and thus early identification of dogs with chronic hepatitis and hepatic fibrosis, 






The histological evaluation of a liver biopsy specimen continues to be the gold standard 
for the assessment of hepatocellular necrosis, inflammation, fibrosis, and for a definitive 
diagnosis of chronic hepatitis. The current lack of robust biomarkers for canine chronic 
hepatitis restricts the non-invasive evaluation of this disease. A number of non-invasive 
biomarkers of hepatocellular injury have been identified and validated in dogs and 
humans. For example, the most widely used biomarker for hepatocellular injury is serum 
alanine aminotransferase activity [5]. Alanine aminotransferase is predominantly found in 
the liver with lower level enzyme activities found in skeletal and cardiac muscle.  Serum 
enzyme activity increases are associated with either reversible or irreversible 
hepatocellular damage [6]. Serum alanine aminotransferase activity has a reported 
sensitivity for detecting histopathologic evidence of hepatocellular injury in symptomatic 
dogs that varies from 60% - 76% [7]. Little is known about the sensitivity of biomarkers 
including alanine aminotransferase to detect hepatobiliary injury in the subclinical disease 
phase. A recent study by Dirksen et al. found that serum alanine aminotransferase and 
alkaline phosphatase activities and serum bile acid concentrations have a sensitivity for 
detecting histologic evidence of copper-associated chronic hepatitis in the subclinical 
phase of 71%, 35%, and 13% respectively [8]. Additionally, serum ALT activity can also 
be increased due to extrahepatic diseases such as pancreatitis, enteritis, and 
endocrinopathies [1]. Therefore, a more sensitive and specific marker of hepatocellular 
injury in dogs with chronic hepatitis would be beneficial.  There is also an unmet need for 
novel non-invasive diagnostic tests for hepatic fibrosis, hepatic function, and hepatic 






Proteomics is the large-scale characterization of the protein complement of a cell, tissue, 
or organism and has emerged as a powerful tool in biomarker discovery. Chronic 
inflammatory hepatobiliary disease has been demonstrated to result in changes to proteins 
found in hepatic tissues in humans [9]. There is one proteomic study of the canine liver to 
the authors knowledge. This study evaluated the soluble liver proteome from bull terriers 
affected with inherited lethal acrodermatitis [10]. Proteomic analysis of canine hepatic 
tissue from dogs with chronic hepatitis may lead to the identification of novel candidate 
biomarkers that could later be evaluated in serum or urine as well as having the potential 
to provide new insights into the pathogenesis of this disease.  
 
The aim of this study was to identify proteins that are differentially expressed between 
hepatic tissue from dogs with chronic hepatitis and healthy control dogs. We hypothesized 
that dogs with chronic hepatitis will exhibit differential hepatic protein expression 
compared to healthy control dogs. 
 Material and methods 
 Patients and procedures 
Eight canine patients undergoing liver biopsy for routine diagnostic purposes that were 
histologically confirmed to have chronic hepatitis and 8 healthy control dogs undergoing 
ovariohysterectomy were enrolled at the Texas A&M University Veterinary Medical 
Teaching Hospital between September 2014 – August 2017. Informed client consent was 
obtained for each patient and the study was approved by the Texas A&M University 
Institutional Animal Care and Use Committee (Animal Use Protocol #2014-320 and 2015-





5 to 8, 5 mm closed cup forceps liver biopsy specimens were collected. The same 5 mm 
closed cup forceps were used to collect 3 – 4 liver biopsy specimens from healthy dogs at 
the time of ovariohysterectomy. One biopsy specimen, approximately 0.5 g of liver tissue 
from each patient was flash frozen in liquid nitrogen within 30 minutes of acquisition and 
stored at -80°C. One liver biopsy specimen was collected in a sterile red top tube for 
copper quantification by atomic adsorption spectroscopy (expressed as µg/g dry weight) 
and another was collected and stored in a sterile specimen cup for aerobic and anaerobic 
culture and susceptibility testing. The remaining liver tissue from dogs in each group was 
fixed in neutral buffered formalin for routine histological processing. Histological sections 
from formalin-fixed paraffin embedded tissues were stained with hematoxylin and eosin, 
picrosirius red, and rhodamine. The diagnosis of chronic hepatitis and healthy control were 
based on clinical signs, routine serum biochemistry panels, and histological assessment of 
liver specimens by a board-certified veterinary pathologist according to the World Small 
Animal Veterinary Association Liver Standardization Group Guidelines [11]. The stage 
of hepatic fibrosis, the grade of necroinflammatory activity, and the semiquantitative 
assessment of copper content were assessed using a previously published scoring scheme 
[2,12]. 
 2-Dimentional Fluorescence Difference Gel Electrophoresis 
 Protein processing and labeling 
Each liver biopsy specimen was placed in a 1.5 mL ground glass pestle and tube tissue 
grinder and homogenized in 10 mM Tris-HCL/1% CHAPS buffer. The overall protein 
concentration was determined by Bradford protein assay using bovine serum albumin as 





choloroform/methanol and dissolved in 1 mL of DIGE labeling buffer (30 mM Tris, 7 M 
urea, 2M Thiourea, 4% CHAPS, pH 8.5 buffer) [13]. Samples were fluorescently labeled 
by reacting 50 μg of protein with 200 pmol CyDye DIGE Fluors (GE Healthcare). One 
sample was labeled with Cy3 while the other was labeled with Cy5 to allow for differential 
labeling. A pooled sample containing equal amounts of each sample was labeled with Cy2. 
The labeling reactions were quenched with 10 mM lysine. 
 2-Dimentional difference gel electrophoresis 
Cy2-, Cy3- and Cy5-labeled samples were mixed together, and rehydration buffer was 
added (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% pharmalytes (GE Healthcare), 40 mM 
dithiothreitol (DTT), and 0.002% bromophenol blue) to a final volume of 450 μl and used 
to rehydrate an immobilized pH gradient strip (24 cm; pH 3–10NL; GE Healthcare) by 
passive diffusion at 20°C for 12h.  Isoelectric focusing was performed on an IPG Phor 3 
horizontal electrophoresis system (GE Healthcare) with a program of 0.5 kV for 1h, 
holding at 0.5 kV for 5 h, ramping to 1 kV over 1 h, ramping to 8 kV over 3 h, holding at 
8 kV until 60 kV*h, and holding at 0.5 kV for 4 h. Each focused strip was then equilibrated 
in two steps: 15 minutes in a reducing equilibration buffer (6 M urea, 50 mM Tris-HCl, 
pH 8.8 with 30% (v/v) glycerol, 2% (w/v) SDS, 0.01 bromophenol, and 10 mg/mL DTT), 
followed by 15 minutes in an alkylating equilibration buffer where DTT was replaced by 
25 mg/mL iodoacetamine. The equilibrated IPG strips were then placed directly on top of 
polymerized 12% SDS gels and sealed with an agarose sealing solution (25 mM Tris, 192 
mM, glycine, 0.1% SDS, 0.5% (w/v) agarose, and 0.02% bromophenol blue). Gels were 
run in cooled tanks with DIGE buffer on an Ettan Dalt-6 (GE Healthcare) at 1 W per gel 





 Image acquisition and analysis 
Gel images were obtained on a Typhoon FLA 9500 (GE Healthcare) at an excitation 
wavelength of 473 nm for Cy2, 532 nm for Cy3, and 635 nm for Cy5 labeled samples. 
The resolution was set at 100 μm. DeCyder 2-D Differential Analysis Software (v 6.5, GE 
Healthcare) was utilized for data analysis. The software subtracts the background signal 
using a subtraction algorithm and quantifies spot intensity based on normalized spot 
volume. The normalization is ratiometric with Cy3 and Cy5 images being expressed as a 
ratio of the corresponding Cy2 internal standard protein spot. Further, DeCyder was also 
used to match spots between gels and determine significant changes in protein expression 
and the absolute fold change ratio. Absolute fold change ratio was derived from the 
normalized spot volume standardized against the intragel standard providing a measure of 
the magnitude of expression differences between identified spots. Protein spots present in 
the gels were matched using Decyder software from which a pick list was generated. Spot 
detection was verified visually. Statistical significance was determined by a two-sided 
student's t-test. Post-hoc testing was performed using Bonferroni’s multiple comparisons 
test and significance was set at q < 0.05. Proteins with an absolute fold change value > 2.0 
between dogs with chronic hepatitis and healthy controls were selected for further 
analysis. All gels were fixed overnight in 10% methanol and 7.5% acetic acid. 
 Spot picking and protein processing 
Ettan Spot Handling Workstations (GE Healthcare, Chicago, IL USA) were used to cut 
out the selected protein spots from a protein gel, perform an in-gel tryptic digestion with 
recombinant porcine trypsin (Promega, Madison, WI) and extract the peptides from the 





achieved by nanoflow liquid chromatography tandem mass spectrometry. Subsequently, 
peptides from the MS were identified using the MASCOT search engine. The MASCOT 
program (v2.2) searched the mouse genome using the following parameters for protein 
identification: 1) one missed cleavage by trypsin; 2) monoisotopic peptide masses; 3) 
peptide mass tolerance of 1.2 Da; and 4) fragment mass tolerance of 0.8 Da. Further, 
oxidation of methionine (variable modification) and carbamidomethylation (fixed 
modification) of cysteine were taken into consideration by MASCOT in the protein 
identification. Peptides were matched to proteins at a minimum of two peptides. Protein 
identification was verified by Scaffold (Proteome Software, Portland, OR). 
 Western blotting 
Select proteins (annexin A5 and cytokeratin 18) that were identified in spots that showed 
differential expression in hepatic tissue from dogs with chronic hepatitis (based on the 2D-
DIGE results) were validated using standard Western blotting techniques. The following 
antibodies were used: annexin V (1:1000, rabbit polyclonal, Abcam, Cambridge, MA, 
USA) and cytokeratin 18 (1:20000, mouse monoclonal, Abcam, Cambridge, MA, USA). 
Liver samples were homogenized in 10 mM Tris-HCL/1% CHAPS buffer. The protein 
concentration was determined with the Bradford protein assay using a bovine serum 
albumin standard. Equal protein loading for each lane was confirmed by immunoblotting 
for anti-Lamin B1 (1:5000, rabbit monoclonal, Abcam, Cambridge, MA, USA). Protein 
samples were boiled following addition of Laemmli loading dye, separated on precast gels 
(BIO-RAD 8-16% Mini-PROTEAN TGX), and transferred to polyvinylidene difluoride 
(PVDF) membranes. PVDF membranes were blocked in 5% milk 0.05% Tween - Tris 





milk 0.05% TTBS overnight at 4ºC. Membranes were washed in 5% milk 0.05% TTBS 
and incubated with an HRP-conjugated anti-rabbit or goat IgG 1/20000 dilution in 5% 
milk 0.05% TTBS. PVDF membranes were washed in 5% milk 0.05% TTBS, incubated 
in ECL-plus, and the signal was detected using an Amersham Imager 600 (GE Healthcare, 
Chicago, IL USA). Densitometry was performed using the ImageQuantTM TL (GE 
Healthcare Life Sciences, Chicago, IL USA) software. 
 Statistical analysis 
Differences between groups were analyzed for statistical significance by two-sided 
student's T-test. Post-hoc testing was performed using Bonferroni’s multiple comparisons 
test. Significance was set at q < 0.05. 
 Results 
 Dog demographics and clinical characteristics 
The demographics and clinical characteristics for the dogs enrolled into the study are 






Table 2.1. Demographics and clinical characteristics of dogs enrolled into the study.  
Reprinted with permission [27]. 
 aAge (years), SF – Spayed female, M – Male, CM – Castrated male, F – Intact female, M 
– Intact male, FIS – Fibrosis score, AS – Activity score, HVS – Hepatocellular vacuolation 
score, CuS – Copper Score, Q Liver Cu – Quantitative liver copper, ALT – Alanine 
transaminotransferase, ALP – Alkaline phosphatase, GGT – Gamma-glutamyl transferase 
 
  
Patient Disease Agea Sex Breed FIS  AS HVS CuS Q Liver Cu ALT  ALP TBILI GGT 
227448 Chronic Hepatitis  12 SF Labrador Retriever 4 2 1 1 667 466 557 0.2 16 
229439 Chronic Hepatitis  6 CM  Doberman Pincher 3 1 0 2 196 989 283 0.3 12 
203392 Chronic Hepatitis  9 M Labrador Retriever 2 2 2 0 463 577 230 0.2 <10 
231640 Chronic Hepatitis  5 M Doberman Pincher 2 2 2 3 3450 750 334 0.2 18 
229216 Chronic Hepatitis  4 SF  German Shorthaired 1 2 1 2 1080 231 98 0.4 <10 
220269 Chronic Hepatitis  11 SF Labradoodle 2 2 2 3 1230 663 179 0.3 22 
175660 Chronic Hepatitis  14 CM  Rat Terrier 3 0 3 0 170 476 327 <0.1 12 
231108 Chronic Hepatitis  9 F Rottweiler Dog 4 1 0 0 257 121 122 0.2 8 
229461 Healthy Control 0.5 F Catahoula Hog Dog 0 0 2  181     
211715 Healthy Control 6 F Greyhound Dog 0 0 0  168     
227893 Healthy Control 1 F Chihuahua 0 0 0  280     
229383 Healthy Control 5 F Staffordshire Terrier 0 0 2  153     
229057 Healthy Control 1 F Labrador Retriever  0 0 1  124     
229382 Healthy Control 3 F Walker Coonhound 0 0 0  96.3     
231847 Healthy Control 0.5 F Labrador Retriever 0 0 0  316     





 Liver biopsy specimens 
All liver biopsies were assessed to be of adequate diagnostic quality with > 12 portal triads 
per biopsy specimen [14]. The liver biopsy specimens of control dogs were free from any 
remarkable histopathological changes. 
 Identification of candidate biomarkers for chronic hepatitis  
Liver tissue specimens from eight dogs with chronic hepatitis and eight healthy control 
dogs were adequate to show a reproducible liver proteome spot pattern of approximately 
2,500 spots. Each spot could contain 1 or multiple proteins. Labeled spots were selected 
for analysis (Fig.1). Image analysis revealed 5 differentially expressed protein spots (q < 
0.05 and fold change > 2.0) that were selected for protein identification.  
 
Altogether 5 differentially expressed protein spots contained 11 different proteins (Table 
2). Spot 1440 showed a 3.18-fold increase in abundance (for chronic hepatitis dogs 
compared to healthy control dogs; q = 0.00095)   and contained annexin 5, regucalin, and 
haptoglobin (Table 1). For protein disulfide – isomerase A4, from spot 472 a 2.33-fold 
increase was detected (q=0.0000325). Additionally, we found a 2.24-fold increase in 
abundance of spot 779 that contained formimidoyltransferase-cyclodeaminase isoform 







Figure 2.1. 2-D gel image of the master gel with labeled picked proteins spots.  
Proteome pattern of canine liver tissue by means of 2D – DIGE. For protein analysis, 
proteins were labeled with Cy2, Cy3, and Cy5, separated in the first dimension using an 
immobilized pH gradient, and subsequently, in the second dimension, by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis. Protein spots were detected using a 
fluorescence scanner (MWM – molecular weight marker; kDA – kilodalton, NL – 







Table 2.2. Summary of proteins identified from differentially expressed spots. 
Reprinted with permission [27]. 
Spot  Identified Protein GENE GO Biological Process Fold Ñ Peptide No. q Value P Value 
1047 Succinyl CoA SUCLG1 cellular metabolic process 2.75 10.00 0.031 0.0062 
1047  Cytokeratinl 8  KRT8 hepatocyte apoptotic process 2.75 6.00 0.031 0.0062 
1047 Cytokeratin 18  KRT18 hepatocyte apoptotic process 2.75 7.00 0.031 0.0062 
1440 Annexin A5 ANXA5 negative regulation of apoptosis 3.18 6.00 0.00095 0.00019 
1440 Regucalcin RGN L-ascorbic acid biosynthesis 3.18 8.00 0.00095 0.00019 
1440 Haptoglobin HP acute - phase response/antioxidant  3.18 3.00 0.00095 0.00019 
460 Protein Disulfide-Isomerase A4 PDIA4 cell redox homeostasis  2.24 3.00 0.00295 0.00059 
460 Gamma-glutamyltransferase 2 TGM3 protein tetramerization 2.24 3.00 0.00295 0.00059 
472 Protein Disulfide-Isomerase A4 PDIA4 cell redox homeostasis  2.33 3.00 3.25E-005 6.50E-006 
779 Formimidoyltransferase FTCD cellular metabolic process 2.24 7.00 3.30E-004 6.60E-005 
779 Annexin A6 ANXA6 apoptotic signaling pathway 2.24 6.00 3.30E-004 6.60E-005 
779 UDP-glucose 6-dehydrogenase  UDGH glycosaminoglycan biosynthesis 2.24 4.00 3.30E-004 6.60E-005 
 
 Analysis of cytokeratin 18 and annexin 5 in the liver of dogs with chronic 
hepatitis using immunoblotting 
 
Two proteins were selected for Western blot analysis. The proteins, cytokeratin 18 and 
annexin 5 were confirmed to contribute to the increased relative abundance in the liver 
proteome of dogs with chronic hepatitis (n = 7, n=4) compared to healthy controls (n = 7, 
n=4), respectively (Table 2; Table 3; Fig. 2 and Fig. 3). Not all dogs were used to conserve 







Figure 2.2. Relative abundance of annexin 5 in the hepatic tissue of dogs with chronic 
hepatitis by Western Blot analysis. Annexin 5 was assessed in the liver proteome of 
7 dogs with chronic hepatitis and compared to 7 healthy control dogs. Lamin was 
used as a loading control.  
Reprinted with permission [27]. 
 
 
Figure 2.3. Relative abundance of cytokeratin 18 in the hepatic tissue of dogs with 
chronic hepatitis by Western blot analysis. Cytokeratin 18 was assessed in the liver 
proteome of 4 dogs with chronic hepatitis and compared to 4 healthy control dogs. 
Lamin was used as a loading control. 







Table 2.3. Patient allocation for Western blot analysis 
Reprinted with permission [27]. 
 
aAge (years), SF – Spayed female, M – Male, CM – Castrated male, F – Intact female, M 
– Intact male, FIS – Fibrosis score, WB – Western blot, CK18 – Cytokeratin 18, ANX5 – 
Annexin 5  
 
 Discussion 
Our study utilized a gel-based, quantitative proteomics approach to identify differentially 
expressed proteins in the liver of dogs with chronic hepatitis compared to healthy control 
dogs. We detected 2,500 protein spots in the liver biopsy samples from dogs. We identified 
5 protein spots that showed differential expression with an absolute fold change of at least 
200% (2.00 absolute fold change) representing 11 proteins was significantly different 
Patient ID# Disease FIS Agea Sex Breed WB CK18 WB ANX5 
227448 Chronic Hepatitis  4 12 SF Labrador Retriever X  
229439 Chronic Hepatitis  3 6 CM  Doberman Pincher X X 
203392 Chronic Hepatitis  2 9 M Labrador Retriever X X 
231640 Chronic Hepatitis  2 5 M Doberman Pincher X X 
229216 Chronic Hepatitis  1 4 SF  German Shorthaired Pointer  X 
220269 Chronic Hepatitis  2 11 SF Labradoodle  X 
175660 Chronic Hepatitis  3 14 CM  Rat Terrier  X 
231108 Chronic Hepatitis  4 9 F Rottweiler Dog  X 
229461 Healthy 0 1 F Catahoula Hog Dog   
211715 Healthy 0 6 F Greyhound Dog X X 
227893 Healthy 0 1 F Chihuahua X X 
227893 Healthy 0 5 F Staffordshire Terrier X X 
229057 Healthy 0 1 F Labrador Retriever   X 
229382 Healthy 0 3 F Treeing Walker Coonhound X X 
231847 Healthy 0 1 F Labrador Retriever  X 





between groups. These proteins warrant investigation as potential biomarkers of canine 
chronic hepatitis. Several of the identified proteins such as cytokeratin 18, cytokeratin 8, 
annexin 5, and annexin 6 are involved with hepatocyte apoptosis. Only cytokeratin 18 and 
annexin 5 were validated by Western blot in this study. All other identified proteins need 
to be validated to confirm these differences. 
 
Hepatocellular apoptosis is a key event in the pathophysiology of many chronic liver 
diseases of dogs and humans, and it is associated with liver fibrogenesis and the 
development of cirrhosis [15-18]. The effector caspases are activated in the final common 
pathway of apoptosis. Cytokeratin 18 is the major intermediate filament protein in the 
liver and the most prominent substrate of caspases during hepatocellular apoptosis [19]. 
Apoptotic cell death of hepatocytes is associated with release of caspase‐cleaved CK18 
fragments in the bloodstream and in contrast, the cytosolic pool of uncleaved CK18 is 
released from hepatocytes during necrosis [20]. Multiple studies have assessed human 
serum or plasma CK18 concentrations and suggested the potential use of CK18 fragments 
as a noninvasive biomarker for the diagnosis or staging of chronic liver disease [21]. 
Furthermore, several studies of nonalcoholic fatty liver disease in humans have 
demonstrated that caspase activation and liver cell apoptosis were prominent features of 
this disease. Additionally, the degree of apoptosis correlated with the severity of hepatitis 
and the stage of fibrosis [22]. Serum CK18 is a marker of hepatocyte apoptosis in humans 
and correlates with histologic activity more accurately than serum alanine 
aminotransferase [23]. Annexin 5A (ANXA5) is a negatively charged phospholipid-





negatively charged phospholipids, such as phosphatidylserine that are exposed on the cell 
surface during apoptosis [24,25]. Increased hepatic annexin 5A expression could therefore 
indicate ongoing apoptosis. Annexin A5 and CK18 have not been previously evaluated in 
canine liver disease. The apoptotic pathway may be altered in canine chronic hepatitis and 
other proteins in this pathway should be further investigated in a targeted study.  
 
This is the first study to evaluate the liver proteome of dogs with chronic hepatitis. 
However, limitations of our study include the heterogeneity of the dogs in the chronic 
hepatitis group with one copper-associated chronic hepatitis case and 7 idiopathic chronic 
hepatitis cases. Examining specific subpopulations of dogs with chronic hepatitis may be 
advantageous. Another limitation is the fact that we only looked at proteins with an 
absolute fold change of > 2.0 between groups to avoid false discovery, which eliminated 
a number of proteins from further analysis. Another limitation is the use of only female 
dogs as a control group; however, the impact of this limitation is unknown. The healthy 
control group dogs were significantly younger than the chronic hepatitis dogs due to 
selection bias. The impact of this limitation is unknown, although, age-related changes in 
the liver proteome have been described in rats [26]. Finally, this initial study has a limited 
sample size that could have led to type II error. Further work that includes measurement 
in blood or urine and validation in a diverse clinical population will be required to establish 
whether the identified proteins have any diagnostic utility.   
 
Proteomic evaluation of liver tissue from dogs with chronic hepatitis demonstrated 





two proteins involved in the apoptotic pathway, cytokeratin 18 and annexin 5 was 
confirmed with Western blotting in these tissues. Further work will be required to establish 
whether these proteins have diagnostic utility over currently available biomarkers. 
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3. UNTARGETED METABOLOMIC PROFILING OF SERUM FROM DOGS WITH 
CHRONIC HEPATIC DISEASE* 
 
 Introduction 
Chronic hepatopathies in dogs represent a spectrum of diseases that include idiopathic 
chronic hepatitis, copper-associated chronic hepatitis, drug-associated chronic hepatitis, 
breed-associated metabolic errors, congenital portosystemic vascular anomalies, lobar 
dissecting hepatitis, and granulomatous hepatitis [1]. Further characterization of metabolic 
changes that occur in these diseases will increase our understanding of disease 
pathophysiology, which may improve disease diagnosis, management, or treatment. 
Although an early accurate diagnosis is important for an improved clinical outcome, 
achieving a definitive diagnosis can be cost prohibitive and invasive with the examination 
of a liver biopsy specimen regarded as the gold standard. The identification of non-
invasive biomarkers that can reliably characterize chronic hepatopathies is desirable and 
may have clinical implications.  
 
The liver is a central organ for regulating metabolism, and a variety of metabolic 
disturbances are seen in patients with chronic liver disease [2,3]. Data from studies in 
human and animal models have documented alterations in hepatic lipid metabolism, 
protein metabolism, energy metabolism, cytokine metabolism, and increased generation 
                                               
* Reprinted with permission from Lawrence YA, Bishop MA, Honneffer JB, Cook AK, Rodrigues-
Hoffmann A, Steiner JM, Suchodolski JS, Lidbury JA (2019) Untargeted metabolomic profiling of serum 
from dogs with chronic hepatic disease. JVIM. Copyright 2019 Lawrence et al. This is an open access article 
distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits 
use, distribution, and reproduction in any medium, provided the original work is properly cited and is not 





of reactive oxygen species in patients with chronic liver disease [4-6]. Global metabolomic 
profiling, the untargeted quantification of small molecules in biologic samples, allows for 
a comprehensive analysis of changes in several metabolic and signaling pathways and 
their interactions [7-9]. This platform utilizes nuclear magnetic resonance spectroscopy or 
mass spectrometry to measure low molecular weight metabolites permitting the formation 
of a metabolite profile. Metabolite profiles can be altered by a variety of physiological and 
pathological processes, and therefore global changes in such profiles may signal the 
presence of a particular disease [10,11]. Characteristic metabolite profiles that can 
discriminate between various types of liver disease have been identified in human studies 
[12-17]. To the authors’ knowledge there are no previous studies that have evaluated 
serum metabolomics in dogs with chronic liver diseases however, a similar study 
examined the plasma metabolome in canine chronic liver disease and found significant 
differences [18].  
 
The present study examined the serum metabolome of dogs with chronic hepatitis, dogs 
with a congenital portosystemic shunt, and clinically healthy dogs. We hypothesized that 
there would be a difference in serum metabolites between groups and that the three groups 
would have significantly different metabolomes. 
 Materials and methods  
 Animals 
Serum was collected from canine patients examined at the Texas A&M University College 
of Veterinary Medicine Veterinary Medical Teaching Hospital between September 2011 





diagnosis of a congenital portosystemic shunt. Informed client consent was obtained for 
each patient and the study was approved by the Texas A&M University Institutional 
Animal Care and Use Committee (Animal Use Protocols #2014-0142, 2014-0320, and 
2015-0043). Patients with chronic hepatitis underwent a laparoscopic liver biopsy and 5 
to 8, 5 mm closed cup forceps liver biopsy specimens were collected. One liver biopsy 
specimen was collected in a sterile red top tube for copper quantification by atomic 
absorption spectroscopy (expressed as µg/g dry weight) and another was collected and 
stored in a sterile specimen cup for aerobic and anaerobic culture and susceptibility testing. 
The remaining liver tissue from dogs with chronic hepatitis was fixed in neutral buffered 
formalin for routine histological processing. Histological sections from formalin-fixed 
paraffin embedded tissue were stained with hematoxylin and eosin, picrosirius red, and 
rhodamine. The diagnosis of chronic hepatitis was based on clinical signs, routine serum 
biochemistry panels, and histological assessment of liver specimens by a board-certified 
veterinary pathologist according to the World Small Animal Veterinary Association Liver 
Standardization Group Guidelines[19] Dogs with a hepatic copper level > 400 µg/g dry 
weight, centrilobular copper accumulation, and an associated inflammatory infiltrate were 
characterized as copper-associated chronic hepatitis. The stage of hepatic fibrosis, the 
grade of necroinflammatory activity, and the semiquantitative assessment of copper 
content were assessed using a previously published scoring scheme [20,21]. Dogs with 
suspected congenital portosystemic shunting based on compatible clinical and/or 
clinicopathologic signs were definitively diagnosed on the basis of two‐dimensional, grey‐
scale ultrasonography as previously described [22]. Dogs with a history of current 





study. All patients with chronic hepatitis or a congenital portosystemic shunt had a 
complete abdominal ultrasound and were accessed for acquired portosystemic shunting 
sonographically as described previously [38]. Dogs with acquired portosystemic shunting 
were excluded from this study. Dogs presented for a wellness examination to the Texas 
A&M University College of Veterinary Medicine Veterinary Teaching Hospital were used 
as healthy controls subsequent to a normal physical examination.  Informed client consent 
was obtained for each dog and sample collection was approved by the Texas A&M 
University Institutional Animal Care and Use Committee Animal Use Protocol #2014-
0251.  
 Serum sample collection 
Serum from all dogs was obtained from non-heparinized whole blood samples that were 
submitted to the clinical pathology service at the Texas A&M University College of 
Veterinary Medicine where serum was separated by means of centrifugation at 2150 × g 
for 10 min at 4°C. Serum biochemical analysis was performed using an Ortho Vitros 4600 
analyzer and the leftover serum was stored at 4°C for less than 72 hours before retrieval 
by study investigators for storage at -80°C. All serum samples were stored for a similar 
length of time. Food was withheld for a minimum of 12 hours prior to blood sample 
collection. 
 Medical record data collection 
The information recorded from the medical record of dogs with chronic hepatitis and 
congenital portosystemic shunting included age, breed, sex, diet, medical treatment at the 
time of enrollment, serum biochemical markers of liver disease, and histologic or 





included age, breed, sex, diet, medical treatment at the time of enrollment, and serum 
biochemical markers of liver disease.  
 Serum metabolome analysis 
Untargeted metabolomics analysis was performed by the West Coast Metabolomics 
Center at the University of California (Davis, CA) on a fee-for-service basis. Serum 
aliquots were extracted by degassed acetonitrile. Internal standards C8-C30 fatty acid 
methyl ethers were added, and the samples were derivatized by methoxyamine 
hydrochloride in pyridine and subsequently by N-methyl-N-
trimethylsilyltrifluoroacetamide for trimethylsilylation of acidic protons. Analytes were 
separated using an Agilent 6890 gas chromatograph (Santa Clara, CA) and mass 
spectrometry was performed on a Leco Pegasus IV time of flight mass spectrometer (St. 
Joseph, MI) following a published protocol [23]. Unnamed peaks were excluded from 
statistical analysis.  
 Statistical analysis 
 Univariate analysis 
Differences in the abundance of serum metabolites between the chronic hepatitis, 
congenital portosystemic shunt, and healthy control groups were evaluated using a 
Kruskal-Wallis test. Univariate analysis was performed using JMP Pro 13 (JMP Software, 
Marlow, England). P-values were adjusted for multiple comparisons using the Benjamini-
Hochberg false discovery rate and significance was set at q < 0.10.[24] Post hoc testing 
was performed with Dunn's Test of multiple comparisons using JMP Pro 13 and 







 Multivariate analysis 
Data reported as peak height were log transformed prior to multivariate analysis. Principle 
component analysis, random forest analysis, and hierarchical cluster analysis was 
performed using MetaboAnalyst 4.0 (http://www.metaboanalyst.ca)[25]. 
 Results  
 Selection criteria of case and control dogs 
There were 12 healthy control dogs enrolled in the study based on a normal physical 
examination and the absence of any reported clinical signs. Three of the 10 dogs with a 
portosystemic shunt had an intrahepatic anomaly, while the other 7 had an extrahepatic 
anomaly. All 10 dogs had blood ammonia concentrations > 50 µ/dL; however compatible 
clinical signs were only reported in four. Three of the six dogs with chronic hepatitis had 
copper-associated chronic hepatitis and 3 had idiopathic chronic hepatitis based on 
histopathologic findings and a quantitative liver copper level. There was no evidence of 
acquired portosystemic shunting in any of the dogs enrolled in this study.   
 Animal population 
The demographics of the healthy control dogs, congenital portosystemic shunt dogs, and 
chronic hepatitis dogs enrolled into the study are summarized in Table 1. Breeds of dogs 
included in each study group are summarized as supplementary data (Supplemental Table 
1). There was no significant difference in the distribution of sexes between groups. There 
was a statistically significant difference in age with chronic hepatitis dogs being older than 
healthy control or congenital portosystemic shunt dogs. There was a statistically 
significant difference in weight with chronic hepatitis dogs weighing more than healthy 





Table 3.1 Control (n=12), congenital portosystemic shunt (n=10), and chronic 
hepatitis (n=6) dog demographics 







Heading Control (n = 12)   Congenital Portosystemic Shunt (n = 10) Chronic Hepatitis (n = 6) p-value  
Age in years (mean +/- SD) 3.75 +/- 1.9 3.3 +/- 2.0 8.67 +/- 4.0 0.0006 
Sex (M/F) 6/6 4/6 2/4 0.78 





Table 3.2 Supplemental Table 1. Control (n=12), congenital portosystemic shunt 
(n=10), and chronic hepatitis (n=6) dog breeds, diet, and medical treatment at time 
of sample collection. AB – antibiotic therapy, L – lactulose therapy, NC – 
nutraceutical therapy (denamarin, and/or ursodiol).   




Group Breed Diet Medical Therapy 
Chronic Hepatitis Rat Terrier Maintenance NC 
Chronic Hepatitis Labrador Retriever Maintenance NC 
Chronic Hepatitis Labradoodle Hill’s l/d AB 
Chronic Hepatitis German Short Haired Pointer Hill’s l/d None 
Chronic Hepatitis Doberman Pincher Hill’s l/d  None 
Chronic Hepatitis German Shepherd Dog Maintenance None 
Control German Shepherd Dog Maintenance None 
Control Australian Shepherd Maintenance None 
Control Pomeranian Maintenance None 
Control Labrador Retriever Maintenance None 
Control Silky Terrier Maintenance None 
Control Cavalier King Charles Spaniel Maintenance None 
Control Mixed Dog Maintenance None 
Control Silky Terrier Maintenance None 
Control Labrador Retriever Maintenance None 
Control Miniature Pinscher Maintenance None 
Control Australian Shepherd Dog Maintenance None 
Control Mixed Dog Maintenance None 
Congenital Portosystemic Shunt Miniature Schnauzer Hill’s l/d  AB 
Congenital Portosystemic Shunt Rhodesian Ridgeback Maintenance None 
Congenital Portosystemic Shunt Shih Tzu Royal Canin Hepatic AB, L 
Congenital Portosystemic Shunt Australian Shepherd Dog Hill’s l/d AB 
Congenital Portosystemic Shunt Australian Heeler Hill’s l/d AB 
Congenital Portosystemic Shunt Mixed Dog Maintenance None 
Congenital Portosystemic Shunt Yorkshire Terrier  Hill’s l/d AB, L 
Congenital Portosystemic Shunt Pug Royal Canin Hepatic AB, L 
Congenital Portosystemic Shunt Lhasa Apso Hill’s l/d None 





 Laboratory and pathology findings 
Serum biochemistry values relevant to hepatic inflammation, cholestasis, and the blood 
ammonia concentration from the dogs with congenital portosystemic shunting are 
summarized in Table 2. Serum biochemistry values relevant to hepatic inflammation, 
cholestasis, and the liver copper level from the dogs with chronic hepatitis are summarized 
in Table 3. The histologic diagnosis and the anatomic pathology scores from the dogs with 
chronic hepatitis are provided as supplementary data (Supplemental Table 2). Serum 
biochemistry values relevant to hepatic inflammation and cholestasis from control dogs 
are provided as supplementary data (Supplemental Table 3). 
Table 3.3 Serum biochemistry variables pertinent to hepatic inflammation and 
cholestasis and blood ammonia in dogs with a congenital portosystemic shunt (n=10). 
Reprinted with permission [39].  
Clinical Pathological Variable Median Range Number (%) of dogs with a result 
outside reference interval 
Reference interval 
Alkaline phosphatase (IU/L) 126.5 38 – 343  3/10 (30) 24 – 147 
Alanine transaminase (IU/L) 181.5 53 – 407  6/10 (60) 10 – 130 
Gamma-glutamyl transferase (IU/L)  12 <10 – 15  0/10 (0) 0 – 25 
Total Bilirubin (mg/dL) 0.35 <0.1 – 0.5  0/10 (0) 0 – 0.8  








Table 3.4 Histologic diagnosis and anatomic pathology scores from dogs with chronic 
hepatitis (n=6). 
Reprinted with permission [39].  
Case No.  Histologic Diagnosis FS AS HVS CS 
1 Copper Associated Chronic Hepatitis 2 2 2 2 
2 Copper Associated Chronic Hepatitis 1 2 1 2 
3 Copper Associated Chronic Hepatitis 3 3 2 3 
4 Idiopathic Chronic Hepatitis 3 1 0 2 
5 Idiopathic Chronic Hepatitis 1 2 3 3 
6 Idiopathic Chronic Hepatitis 3 0 3 0 
 
FS – fibrosis score, AS – activity score, HVS – hepatovacuolization score, CS – copper score 
 
 
Table 3.5. Serum biochemistry variables pertinent to hepatic inflammation and 
cholestasis and hepatic copper concentrations in dogs with chronic hepatitis (n=6). 
Reprinted with permission [39].  




Alkaline phosphatase (IU/L) 283 98 – 481 4/6 (66.7) 24 – 147 
Alanine transaminase (IU/L) 519 231 – 989 6/6 (100) 10 – 130 
Gamma-glutamyl transferase 
(IU/L)  
12 <10 – 32 1/6 (16.7) 0 – 25 
Total Bilirubin (mg/dL) 0.3 <0.1 – 0.4 0/6 (0) 0 – 0.8  
Tissue copper (µg/g dry weight) 494.5 170 – 
1080  
3/6 (50) 120 - 400 
 
 
Table 3.6. Serum biochemistry variables pertinent to hepatic inflammation and 
cholestasis in control dogs (n=10). 
Reprinted with permission [39].  




Alkaline phosphatase (IU/L) 126.5 38 – 343  0/10 (0) 24 – 147 
Alanine transaminase (IU/L) 181.5 53 – 407  0/10 (0) 10 – 130 
Gamma-glutamyl transferase (IU/L)  12 <10 – 15  0/10 (0) 0 – 25 







 Effect of congenital portosystemic shunting and chronic hepatitis on serum 
metabolomics 
A total of 126 named serum metabolites were identified of which 50 differed significantly 
(p£ 0.05; q<0.10) between healthy control dogs, congenital portosystemic shunt dogs, and 
chronic hepatitis dogs (Table 4). Principle component analysis plots showed a clustering 
of the variables based on disease classification (Figure 1). The distribution of the most 
significant metabolites separating the three experimental groups was visualized with a heat 
map (Figure 2). Every column represents a different sample and each box represents a 
metabolite in the sample. Increased abundances are shaded red, whereas decreased 
abundances are shaded blue. The congenital portosystemic shunt group showed greater 
abundances of the aromatic amino acids tyrosine and phenylalanine and a decreased 
abundances of the branched chain amino acids leucine, isoleucine, and valine when 
compared to healthy dogs and dogs with chronic hepatitis. Random forest analysis 
identified metabolites that had the highest discriminatory power between the three groups 
(Figure 3). Individual compounds in serum that contributed the most to the accuracy of 
disease classification are shown in Figure 3. A subset of those highly-discriminatory 






Table 3.7 Serum metabolites that differed significantly between healthy control dogs 
(n=10), dogs with a congenital portosystemic shunt (n=12), and dogs with chronic 
hepatitis (n=6). KW – Kruskal – Wallis Test. 
Reprinted with permission [39].  
Compound Name p.value_KW q.value_KW 
xylitol 4.70E-05 0.0036214 
phenylalanine 5.75E-05 0.0036214 
valine 0.00018392 0.0062971 
tyrosine 0.00023471 0.0062971 
phenylethylamine 0.00029986 0.0062971 
cysteine 0.00026692 0.0062971 
serine 0.00042437 0.0070513 
leucine 0.00050367 0.0070513 
2-deoxypentitol  0.00047524 0.0070513 
methionine 0.00068492 0.0084815 
ethanolamine 0.00074045 0.0084815 
threonine 0.00090305 0.0088613 
3-phenyllactic acid 0.00091426 0.0088613 
arachidic acid 0.0010602 0.0095421 
lactamide 0.0017013 0.014291 
methionine sulfoxide 0.001935 0.014342 
hypoxanthine 0.0019338 0.014342 
isoleucine 0.0021926 0.015348 
trans-4-hydroxyproline 0.0025673 0.017025 
succinic acid 0.0032266 0.01848 
mannose 0.0032044 0.01848 
creatinine 0.0031961 0.01848 
uric acid 0.0039235 0.021196 
inosine 0.0040372 0.021196 
pyruvic acid 0.0046021 0.023195 
pseudo uridine 0.0053592 0.025971 
stearic acid 0.0061125 0.027506 
aspartic acid 0.0059262 0.027506 
glycolic acid 0.007269 0.031583 
2-deoxytetronic acid 0.0078535 0.032985 
myristic acid 0.010268 0.041736 





Table 3.7 Continued 
Compound Name p.value_KW q.value_KW 
thymidine 0.01279 0.048833 
4-hydroxyphenylacetic acid 0.013265 0.049157 
ribonic acid 0.015176 0.054359 
proline 0.015531 0.054359 
sucrose 0.01748 0.059429 
myo-inositol 0.017923 0.059429 
urea 0.019469 0.062901 
uracil 0.020081 0.063256 
ribose 0.022043 0.066128 
cytosin 0.02172 0.066128 
2-ketoisocaproic acid 0.025132 0.073642 
conduritol-beta-epoxide 0.028493 0.081594 
citric acid 0.033803 0.090622 
allantoic acid 0.033014 0.090622 
4-hydroxymandelic acid 0.033103 0.090622 
pipecolinic acid 0.035076 0.092074 






Figure 3.1 Principal component analysis of the serum metabolome showing 
clustering of samples based on group.  







Figure 3.2 . Heatmap of the most abundant metabolites in all groups, as identified 
by VIP scores in PLS-DA.  
 
Each sample is represented by a single column. The higher the intensity of the red color, 
the higher the abundance of the metabolite (CPSS – Congenital portosystemic shunt; CH 










Figure 3.3 Top 15 metabolites in serum (left panel) in rank order of importance for 
differentiating between control dogs, congenital portosystemic shunt dogs, and 
chronic hepatitis dogs.  
 
Data were generated by Random Forest analysis. Compounds contributing the most to the 
accuracy of disease classification were identified as those having the highest mean 
decrease accuracy (MDA) of the predicted classification when permuted within the 









Figure 3.4 Branch chain amino acids and aromatic amino acids identified as potential 
biomarkers of congenital portosystemic shunting and chronic hepatitis in dogs.  
 
Each metabolite was identified by Random Forest or univariate analysis as important for 
differentiation of dogs into either control, congenital portosystemic shunt, or chronic 
hepatitis groups. The abundance of phenylalanine was significantly increased in dogs with 
a congenital portosystemic shunt compared to control dogs and the abundance of tyrosine 
was significantly increased in dogs with a congenital portosystemic shunt compared to 
control dogs and chronic hepatitis dogs. The abundance of leucine, isoleucine, and valine 
was significantly decreased in dogs with a congenital portosystemic shunt compared to 





Figure 4. Branch chain amino acids and aromatic amino acids identified as potential biomarkers of congenital portosystemic shunting and chronic hepatitis in dogs.
Each metabolite was identified by Random Forest or univariate analysis as important for differentiation of dogs into either control, congenital portosystemic shunt,
or chronic hepatitis groups. The abundance of phenylalanine was significantly increased in dogs with a congenital portosystemic shunt compared to control dogs
and the abundance of tyrosine was significantly increased in dogs with a congenital portosystemic shunt compared to control dogs and chronic hepatitis dogs. The




























































Figure 3.5 Selected serum metabolites with potential value as biomarkers of a 
congenital portosystemic shunt or chronic hepatitis dogs.  
 
Each metabolite was identified by Random Forest and/or univariate analysis as important 
for the differentiation of dogs into either control, congenital portosystemic shunt, or 
chronic hepatitis groups. The serum abundance of trans-4-hydroxy-l-proline was 
significantly increased in control dogs compared to dogs with a congenital portosystemic 
shunt or chronic hepatitis. The serum abundance of xylitol was significantly decreased in 
control dogs compared to dogs with a congenital portosystemic shunt or chronic hepatitis. 






This study identified extensive metabolic abnormalities in the serum of dogs diagnosed 
with a congenital portosystemic shunt or chronic hepatitis, with significant alterations in 
50 of 126 named serum metabolites. These metabolites are known to be involved in a 
variety of processes, including aminoacyl-tRNA biosynthesis, branch chain amino acid 
biosynthesis and degradation, proline metabolism, phenylalanine metabolism, citrate 
cycle, and pantothenate and coenzyme A biosynthesis.  
 Abnormal amino acid metabolism 
Significant abnormalities were observed in the state of conjugation and the relative 
amounts of individual amino acids in dogs with congenital portosystemic shunts and dogs 








































Congenital Portosystemic Shunt Dogs
Chronic Hepatitis Dogs
Figure 5. Selected serum metabolites with potential value as biomarkers of a congenital portosystemic shunt or chronic hepatitis dogs. Each
metabolite was identified by Random Forest and/or univariate analysis as important for the differentiation of dogs into either control, congenital
portosystemic shunt, or chronic hepatitis groups. The serum abundance of trans-4-hydroxy-l-proline was significantly increased in control dogs
compared to dogs with a congenital portosystemic shunt or chronic hepatitis. The serum abundance of xylitol was significantly decreased in control





significant increase in the abundance of the aromatic amino acids (AAAs) tyrosine and 
phenylalanine, and a significant decrease in the branched chain amino acids (BCAAs), 
leucine, isoleucine, and valine in dogs with a congenital portosystemic shunt (Figure 4). 
The decreased serum ratio of BCAAs to AAAs characterized of hepatic cirrhosis in 
humans and is attributable to several factors, including reduced nutritional intake, 
hypermetabolism, and ammonia detoxification by skeletal muscle [26]. A low serum 
BCAA/AAA ratio reduces biosynthesis and secretion of albumin in hepatocytes, and is 
also associated with a less favorable prognosis in human patients with chronic liver disease 
[27,28]. BCAAs are a constituent of protein and in addition are a source of glutamate, 
which detoxifies ammonia by glutamine synthesis in skeletal muscle [26]. The changes in 
the metabolism of BCAAs and AAAs that occur in liver disease may also have a role in 
the pathogenesis of end-stage liver disease complications, such as hepatic encephalopathy 
and hypoalbuminemia [29]. Additionally, the serum concentration of the AAA tyrosine 
has been found to increase early in the course of chronic liver disease in humans and to 
positively correlate with histologic fibrosis scores [30]. A low serum BCAA/AAA ratio 
was only observed in dogs with a congenital portosystemic shunt and may represent 
decreased hepatic function due to hypoperfusion consistent with previous studies [31,32]. 
This was not observed in the dogs in this study with chronic hepatitis, however none of 
these dogs had any evidence of acquired portosystemic shunting. The BCAA/AAA ratio 
is considered an indicator of hepatic insufficiency that decreases with the severity of 
hepatic dysfunction or porto-systemic shunting [32]. Further studies evaluating the 
BCAA/AAA ratio over the course of chronic liver disease in dogs and dogs with acquired 





examine the serum metabolome of dogs with chronic liver disease with an untargeted 
approach. Additional research to characterize the role of these metabolic changes in 
disease diagnosis, stratification, and treatment is warranted.  
 Potential biomarkers for dogs with a congenital portosystemic shunt and dogs 
with chronic hepatitis 
A number of compounds in serum were individually identified for their value in 
distinguishing between healthy dogs, dogs with chronic hepatitis, and dogs with 
congenital portosystemic shunts. Random forest analysis identified 15 metabolites that 
were able to differentiate dogs with congenital portosystemic shunts (100% accuracy) and 
dogs with chronic hepatitis (83% accuracy) from apparently healthy dogs (Figure 3). 
There was a significant decrease in serum proline and hydroxyproline in the dogs with a 
congenital portosystemic shunt and dogs with chronic hepatitis compared to healthy 
control dogs (Figure 5). Hydroxyproline is a non-proteinogenic amino acid that is fairly 
specific to collagen in mammals and its serum concentration reflects collagen metabolism 
in tissues with a high metabolic turnover of this protein [33]. Additional research is 
warranted to determine the significance of this finding for collagen metabolism in canine 
patients with hepatic fibrosis and the role of this molecule as a marker of disease 
progression. There was also a significant increase in xylitol in the serum of dogs with 
chronic hepatitis and dogs with a congenital portosystemic shunt compared to healthy 
control dogs (Figure 5). Xylitol, a five-carbon polyalcohol is widely distributed in nature 
with trace amounts of xylitol produced by animals [34]. Although xylitol can enter almost 
all cells of an organism the liver cells are especially permeable [34]. This molecule, which 





humans with liver disease [17,35,36]. The role of this metabolite in liver disease has not 
been fully characterized.  
 Future potential medical strategies 
There are limited evidence-based strategies for the medical management of dogs with 
chronic hepatitis or a congenital portosystemic shunt. A number of compounds identified 
in this study have a potential therapeutic role in the management of patient with liver 
disease. Studies in humans have shown that the intravenous or oral supplementation of 
BCAAs improves not only nutritional status, but also prognosis and quality of life in 
patients with chronic liver disease [14]. The presence and impact of a significant 
deficiency or over-abundance of any of these compounds will require validation in a 
targeted quantitative analysis. 
 Study limitations 
Limitations of this study would include the influence of concurrent drug administration 
on our findings and the lack of inclusion of a group of dogs with other forms of hepatic 
disease such as acute hepatitis. Some of our findings may also be observed in dogs with 
extra-hepatic disease and the effect of diet on circulating metabolites was not considered. 
Control dogs were not assessed for portosystemic shunting; therefore, the possibility of 
subclinical portosystemic shunting in this group exists. These findings will need to be 
validated in a prospective targeted study in healthy control dogs, chronic hepatitis dogs, 
congenital portosystemic shunt dogs, and dogs with other forms of hepatic or 
gastrointestinal disease. Another limitation of the study reported here is the discrepancy 
in the ages of dogs with chronic hepatitis compared to healthy control dogs and dogs with 





some compounds simply on the basis of a difference in age between these groups of dogs. 
Since metabolites in serum are affected by the cumulative effect of complex physiological 
processes across all tissues in the body, it is not possible to definitively determine the 
organ, cell type, or intracellular compartment from which identified compounds 
originated. Furthermore, the impact of renal excretion versus reabsorption, and intestinal 
microbial metabolism on the types and quantity of compounds detected in the serum is 
unknown. Metabolomic investigation of the urine of dogs with chronic hepatitis and 
congenital portosystemic shunting compared to healthy control dogs would provide 
considerable additional insight into the metabolic abnormalities identified in this study.   
 Conclusion 
The untargeted metabolomic profiling of serum from dogs with chronic hepatitis or dogs 
with a congenital portosystemic shunt demonstrated significant semi-quantitative 
differences in 50 of 126 named serum metabolites, including branch chain amino acids, 
aromatic amino acids, xylitol, and hydroxyproline. Further validation of these results in a 
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4. DEVELOPMENT, VALIDATION, AND APPLICATION OF A LC-MS/MS 
METHOD FOR THE QUANTITATIVE DETERMINATION OF TRANS-4-
HYDROXY-L-PROLINE IN THE SERUM OF DOGS WITH CHRONIC HEPATITIS* 
 
 Introduction 
Chronic hepatitis is the most common liver disease in dogs [1]. The cause of chronic 
hepatitis in dogs is often unknown and called idiopathic chronic hepatitis. Recognized 
causes of chronic hepatitis in dogs include hepatic accumulation of copper and drug-
induced liver injury. Chronic hepatitis is histologically characterized by hepatocellular 
apoptosis or necrosis, a variable mononuclear or mixed inflammatory infiltrate, 
regeneration, and fibrosis [1]. The prognosis for dogs with chronic hepatitis is guarded, 
with variable progression to end-stage liver disease and fibrosis. Fibrosis is defined by the 
overgrowth, hardening, and scarring of various tissues and is attributed to excess 
deposition of extracellular matrix components, including collagen [2]. Efforts have been 
made to replace examination of liver biopsy specimens with measurement of noninvasive 
markers of liver fibrosis to aid in diagnosis and monitoring response to treatment in dogs 
with liver disease.  
 
                                               
* Reprinted with permission from Lawrence YA, Rodrigues-Hoffman A, Steiner JM, Shankar S, 
Klemashevich CL, Lidbury JA. Development, validation, and application of a LC-MS/MS method for the 
quantitative determination of trans-4-hydroxy-l-proline in the serum of dogs with chronic hepatitis. 2019. 






Complications of cirrhosis or end-stage liver disease are the primary causes of death 
related to chronic hepatic diseases. Progressive liver fibrosis resulting in the development 
of end-stage liver disease is characteristic of chronic liver disease; thus, the assessment of 
liver fibrosis can be a predictive factor for liver-related fatalities. The stage of liver fibrosis 
has been correlated with mortality rates and prognosis in chronic hepatic diseases of dogs 
[3,4] and humans [5]. Noninvasive markers of liver fibrosis are desired.   
 
Trans-4-hydroxy-L-proline is a nonproteinogenic, nonessential amino acid found in 
collagen and other extracellular proteins. Trans-4-hydroxy-L-proline is an important 
constituent of collagen and is a collagen-specific amino acid, with approximately 1% of 
the amino acid found in elastin [6]. Serum trans-4-hydroxy-L-proline concentration has 
been correlated with fibrosis in humans with chronic hepatic disease [7,8].  
 
The purpose of the study reported here was to develop and validate a simple, efficient, and 
reliable LC-MS-MS method for the quantitative determination of endogenous trans-4-
hydroxy-L-proline in canine serum. The clinical applicability of the method was assessed 
by analyzing the trans-4-hydroxyl-L-proline content in the serum of dogs with chronic 
hepatitis. We hypothesized that dogs with chronic hepatitis would have higher serum 
concentrations, compared with concentrations in healthy control dogs. 
 Materials and methods 
 Samples 
Blood samples previously collected from 20 dogs with histologically confirmed chronic 





University Veterinary Teaching Hospital from November 2014 through December 2015 
were used for the study. Blood samples were immediately centrifuged at 1,800 X g for 10 
minutes at 4°C; serum was harvested and stored at −80°C until analysis. For dogs that 
underwent laparoscopic liver biopsy or exploratory celiotomy with surgical liver biopsy 
and removal of bile from the gallbladder as part of standard diagnostic testing, a 1-mL 
sample of bile and 1 additional liver biopsy specimen were collected for an unrelated 
unpublished study. Four to 6 liver biopsy specimens were acquired during a typical liver 
biopsy. Of these, 1 biopsy specimen was placed in a sterile red top tube and used for tissue 
copper quantification, 1 biopsy specimen was placed in a sterile specimen cup and 
submitted for aerobic and anaerobic bacterial culture and susceptibility testing, and 1 to 3 
biopsy specimens were fixed in neutral-buffered formalin, processed for routine histologic 
examination, and embedded in paraffin. Serial sections of liver tissue were stained with 
H&E, eosin, or Picrosirius Reda stains or a combination of these stains. Hepatic fibrosis, 
inflammation, and hepatocellular vacuolation were scored by a single board-certified 
veterinary pathologist who was not aware of the clinical data; scores were assigned by use 
of an established 5-point scoring system (0 = absent, 1 = mild, 2 = moderate, 3 = marked, 
and 4 = very marked). Informed client consent was obtained for each dog, and the study 
was approved by the Texas A&M University Institutional Animal Care and Use 
Committee (animal use protocols No. 2017-0351CA and 2015-0043). 
 LC-MS-MS 
The LC-MS-MS system consisted of a high-performance liquid chromatography systemb 
and a mass spectrometer.c Sample acquisition and data analysis were performed with 





The mobile phase consisted of 0.1% formic acid (solvent A) and 0.1% formic acid in 
methanol (solvent B). The gradient was 0 to 5 minutes, 10% solvent B to 40% solvent B; 
5 to 7 minutes, 40% solvent B to 95% solvent B; 7 to 9 minutes, 95% solvent B;  9 to 9.1 
minutes, 95% solvent B to 10% solvent B; and 9.1 to 13 minutes, 10% solvent B. Injection 
volume was 10 µL, total assay time was 13.1 minutes, and flow rate was 0.4 mL/min.  
 
The mass spectrometer was operated with electrospray ionization in the positive ion mode. 
Instrument parameters and transitions were optimized, with flow infusion set at a rate of 
10 µL/min. Electrospray parameters used were static spray voltage of 3,500 V, ion transfer 
tube temperature of 325°C, and vaporization temperature of 350°C. Sheath gas, auxiliary 
gas, and sweep gas were 45, 13, and 1 Arb, respectively. Collision gas was at 200 Pa. 
Injector needles were washed with water and acetonitrile between successive injections. 
Autosampler carryover was monitored by performing blank injections. Column 
performance was monitored by measuring retention times. 
 Standard solutions, calibrations, and internal control samples 
Trans-4-hydroxy-L-prolinef (purity ³ 99%) and trans-4-hydroxy-L-proline-2,5,5-D3g 
(purity > 98%) were used as internal standards. High-performance liquid 
chromatography–grade acetonitrileh was purchased, and 18 MOhm water was purified 
with a water purification system.i  
 
Stock solutions (concentration, 0.1 mg/mL) were prepared by dissolving 0.1 mg of D3-
trans-4-hydroxy-L-proline in 1 mL of water. Standard working solutions were then 





10, 25, 50, 100, and 250 ng/mL. Calibration standards were prepared by spiking 50 µL of 
blank canine serum with a freshly prepared working solution to achieve concentrations of 
0.5, 1, 2.5, 5, 10, 25, 50, 100, and 250 ng/mL; solutions were then extracted with 100% 
acetonitrile to achieve standard solutions with concentrations of 0.005, 0.01, 0.025, 0.05, 
0.1, 0.25, 0.5, 1, and 2.5 ng/mL. 
 Sample preparation 
Canine serum samples (50 µL) were thawed at room temperature (21°C) and placed in a 
1.5-mL Eppendorf tube; 200 µL of 100% acetonitrile was added, and the mixture was 
mixed in a vortex device. Samples were then centrifuged at 17,500 X g at 4°C for 5 
minutes. An aliquot (200 µL) of supernatant was transferred to a clean 1.5-mL Eppendorf 
tube. Another 50 µL of supernatant was transferred to a 2-mL glass vial with a glass insert; 
a sample of 10 µL was removed from this glass vial and injected into the LC-MS-MS 
system. 
 Analytic validation 
The LC-MS-MS method was analytically validated in accordance with US FDA 
guidelines10 with respect to linearity, accuracy, precision, and recovery. 
 Linearity 
Linearity of the assay was tested on 6 replicates of each of 3 concentrations of DQCs (2X, 
5X, and 10X); the DQCs were dilutions of a high concentration (5.0 ng/mL) of a quality 
control standard solution. Calculated concentration measurements were compared to the 







Selectivity of the method was assessed by comparing chromatogram responses of 6 lots 
of naïve canine serum with canine serum spiked with the internal standard. 
 Calibration curve and the LLOQ 
Calibration standards were prepared by spiking canine serum samples with 0.5 µL of 
working standard solutions or the internal standard. A calibration curve was constructed 
with a linear range of 0.01 to 2.50 ng/mL. Calibration curves were prepared for each 
analytic run by plotting the back-calculated concentration against the nominal 
concentration. Linearity was assessed by use of linear regression with appropriate 
weighting. The LLOQ was determined to be acceptable when 5 replicates of the lowest 
calibration standard had accuracy and precision deviations of < 20%. 
 Accuracy and precision 
Accuracy was evaluated for 4 quality control samples on 5 consecutive days. Accuracy 
was determined as the percentage difference between the mean of observed concentrations 
and the theoretical concentration (relative error); this value was required to be within ± 
10% for all samples. Intra-assay and inter-assay precision was determined by assaying 3 
samples at each of 3 quality control concentrations in 5 assays and on 5 consecutive days, 
respectively. The CV was used to express precision; CV values were required to be ≤ 10%. 
 Recovery 
Recovery was determined by comparing the peak areas of extracted endogenous samples 
with low, mid, and high concentrations (1.8, 2.8, and 4.8 ng/mL, respectively) with the 





calculated by dividing peak areas of the analyte obtained for the extracted exogenous 
samples with those of postextraction spiked samples. 
 Matrix effect 
Matrix effect of canine serum on the analysis of trans-4-hydroxy-L-proline concentrations 
was determined by comparing peak areas of the analyte in extracted blank serum samples 
to those obtained for standard solutions at the corresponding concentrations. The matrix 
effect was evaluated at 3 quality control concentrations (0.01, 0.10, and 0.50 ng/mL). 
 Statistical analysis 
Differences between groups were analyzed for statistical significance by the Mann-
Whitney U and Kruskal-Wallis test where appropriate using commercially available 
software.j Significance was set at p < 0.05. 
 Results 
 Sample 
Serum samples were obtained from 20 dogs with chronic hepatitis and 20 healthy control 
dogs. The dogs with chronic hepatitis comprised 9 Labrador Retrievers, 4 Doberman 
Pinchers, 4 crossbreds, 1 Dachshund, 1 Rat Terrier, and 1 Vizla. There were 11 spayed 
females, 6 castrated males, 2 sexually intact males, and 1 sexually intact female. Fibrosis 
score was 1 for 3 dogs, 2 for 9 dogs, 3 for 6 dogs, and 4 for 2 dogs. Median age of the 
dogs was 9 years (range, 3 to 9 years). The healthy dogs comprised 4 Labrador Retrievers, 
3 crossbreds, 2 Boston Terriers, 2 Golden Retrievers, and 1 each of Alaskan Malamute, 
American Bull Terrier, Australian Shepherd, Boxer, Chihuahua, English Cocker Spaniel, 
Miniature Schnauzer, Schipperke, and Siberian Husky. There were 9 castrated males, 8 





dogs was 3 years (range, 0.5 to 12 years). The dogs with chronic hepatitis were 
significantly (P = 0.007) older than the control dogs. 
 LC-MS-MS 
Fragment ion spectra, including quantification and confirming ions, of trans-4-hydroxy-
L-proline and the deuterated internal standard D3-trans-4-hydroxy- L-proline were m/z 
132 and m/z 135.1, respectively (Figure 1). Trans-4-hydroxy- L-proline and the internal 
standard D3-trans-4-hydroxy- L-proline were detected under optimized conditions (Figure 
2). There were no substantial interfering peaks for blank canine serum at the retention 
times of trans-4-hydroxy-L-proline and D3-trans-4-hydroxy-L-proline. 
 Calibration and linearity 
The calibration curve for trans-4-hydroxy-L-proline in canine serum was linear over the 
concentration range of 0.01 to 2.50 ng/mL (r = 0.9997) and had consistent slope values 
when evaluated by use of weighted (1/2X) linear regression. The equation for the slope of 
the calibration curve of trans-4-hydroxy-L-proline was y = 9,000,000x – 69,198, and the 
LLOQ was 0.005 ng/mL. 
 Precision and accuracy 
Intra-day and interday precision and interday accuracy were determined for measurement 
of trans-4-hydroxy-L-proline in canine serum. Intraday precision (CV) for measurement 
of trans-4-hydroxy-L-proline in canine serum ranged from 2.1% to 3.0% (Table 1). 
Interday precision (CV) for measurement of trans-4-hydroxy-L-proline in canine serum 
ranged from 3.2% to 5.3%. Interday accuracy (relative error) for measurement of trans-4-






Table 4.1.—Precision and of LC-MS-MS analysis of the trans-4-hydroxy-l-proline 
concentration in canine serum. 
Reprinted with permission [22].     
Sample  Measured mean ± SD (ng/mL) Precision (%) * 
Intraday (n = 5)    
  1   0.81 ± 0.03    3.0 
  2   1.75 ± 0.04    2.1 
  3   4.26 ± 0.12    2.5 
 
Interday (n = 5)   
  1   0.81 ± 0.05    5.3 
  2   1.72 ± 0.09    4.5 
  3   4.23 ± 0.15    3.2 
 
*Precision represents the CV. 
 
Table 4.2.—Accuracy of LC-MS-MS analysis of the trans-4-hydroxy-l-proline 
concentration in canine serum. 
Reprinted with permission [22].     
Nominal concentration (ng/mL   Measured mean ± SD (ng/mL)      Accuracy (%) * 
0.10            0.10 ± 0.001             –0.5 
0.25            0.24 ± 0.010    5.5 
0.50            0.46 ± 0.010    7.8 
1.00            1.02 ± 0.010             –2.3 
 
*Accuracy was evaluated for 4 quality control samples on 5 consecutive days and is 
reported as the relative error.  
 
 Recovery 
Extraction recovery was calculated by comparing the peak areas of extracted endogenous 
canine serum samples with low, mid, and high concentrations with those of postextraction 
spiked samples. Recovery for trans-4-hydroxy-L-proline was 48.9% for 1.8 ng/L, 55.1% 






 Matrix effect 
A possible matrix effect was evaluated for 3 concentrations during method development 
of the assay for measurement of trans-4-hydroxy-L-proline in canine serum (Table 3). 
Overall mean matrix effect of blank serum was 25.1%. 
Table 4.3.—Matrix effect of canine serum on the trans-4-hydroxy-L-proline 
concentration. 
Reprinted with permission [22].  
Observed concentration Peak area when dissolved Peak area when dissolved             Matrix effect (%) 
(ng/mL)   in matrix serum (arb. unit)  in mobile phase (arb. unit)    
0.01   93,223   116,247    19.8 
0.10   738,634   1,187,546   37.8 
0.50   3,570,732  4,334,020   17.6 
 
 Assessment for clinical application 
Median concentration of trans-4-hydroxy-L-proline in the serum of dogs with chronic 
hepatitis (0.24 ng/mL) was significantly (P = 0.007) lower than the median concentration 
in the serum of healthy control dogs (0.78 ng/mL; Figure 3). Concentration of trans-4-
hydroxy-L-proline for dogs with mild fibrosis (fibrosis score, 1 or 2) was significantly (P 
= 0.02) lower that of healthy control dogs (0.20 and 0.78 ng/mL, respectively). There was 
not a significant difference in concentrations between dogs with mild or marked (fibrosis 
score, 3 or 4) fibrosis and between dogs with marked fibrosis and healthy control dogs 
(Figure 4). 
 Discussion 
An LC-MS-MS method for the quantification of trans-4-hydroxy-L-proline in canine 
serum was developed and analytically validated in the study reported here. Linearity of 





indicated a strong correlation between the peak area ratio and the concentration of trans-
4-hydroxy-L-proline in the linear range.  The method described had a linear range of 0.01 
to 2.50 ng/mL, and the LLOQ was 0.005 ng/mL. Selectivity for trans-4-hydroxy-L-proline 
was indicated by identification of the peak without interference. Intraday and interday 
precision and accuracy were within 15%, as stipulated by FDA guidelines. Mean 
percentage recovery was 50.4%; however, recoveries for trans-4-hydroxy-L-proline and 
the deuterated internal standard were consistent and similar, which allowed adjustment of 
the low recovery and fulfilled FDA validation guidelines. The method had acceptable 
performance in terms of sensitivity (ie, LLOQ), precision, and accuracy and had a 
relatively short run time for analysis and relatively simple sample preparation. Trans-4-
hydroxy-L-proline concentrations were significantly lower in the serum of dogs with 
chronic hepatitis, compared with concentrations in serum of healthy control dogs.  
 
Hydroxyproline is fairly specific for collagen in mammals, and serum concentrations of 
hydroxyproline are a reflection of collagen metabolism in tissues with a high metabolic 
turnover of this protein [11]. The quantity of hydroxyproline in the liver of rats [12,14], 
humans [13], and dogs [15] were increased in proportion to the degree of hepatic fibrosis. 
During conditions of increased fibrogenesis (eg, hepatic fibrosis), serum concentrations 
of hydroxyproline are increased in humans [7] and rats [21]. 
 
Results of the present study that indicated lower serum hydroxyproline concentrations in 
dogs with chronic hepatitis than in control dogs were unexpected. The healthy control 





serum biochemical values, and results of liver function testing. However, the possibility 
of occult histologic liver disease cannot be completely excluded without examination of 
liver biopsy specimens. Although hydroxyproline is relatively specific for collagen, 
increased tissue concentrations have also been detected in patients with fibrotic pulmonary 
disease [16], fibrotic cardiac disease [17], and fibrotic renal disease [18]. The effect of 
fibrosis in nonhepatic organs on serum hydroxyproline concentrations is unknown and 
was not examined in the present study. The possibility of concurrent or occult nonhepatic 
fibrosis cannot be excluded, and the effect on serum hydroxyproline concentrations could 
not be determined in the study reported here.  
 
The serum concentration of hydroxyproline in dogs with mild hepatic fibrosis were lower 
than in healthy control dogs in the present study; evaluation of a larger group of dogs with 
a wider range of fibrosis scores may be warranted. Serum hyperprolinemia in humans is a 
specific feature of alcoholic liver cirrhosis [6,8]. Human patients with nonalcoholic 
cirrhosis or other forms of chronic liver disease have serum proline and hydroxyproline 
concentrations indistinguishable from those of healthy control subjects [6,8]. On the other 
hand, patients with alcoholic hepatitis have serum proline and hydroxyproline 
concentrations significantly higher than those in patients with other forms of liver disease 
[6,8]. It has been hypothesized that alcohol inhibits proline metabolism or facilitates its 
release from hepatocytes [6,8]. The pathophysiology of alcohol-induced serum 
hyperprolinemia in humans with chronic hepatitis likely differs from that of dogs with 






Trans-4-hydroxy-L-proline was significantly lower in the serum of dogs with chronic 
hepatitis than in the serum of healthy control dogs (median concentrations of 0.20 and 
0.78 ng/mL, respectively. Age-related changes in the liver have been described in humans 
and includes a decrease in volume, decrease in blood flow, mitochondrial dysfunction, and 
an increase in susceptibility to fibrosis [19]. Age-related fibrosis has not been 
characterized in humans. The groups of dogs were not matched on the basis of age in the 
study reported here. The serum available for the control group was obtained from dogs 
owned by veterinary students and faculty and staff of the veterinary teaching hospital, and 
these dogs typically were young. Therefore, we cannot rule out that the difference in the 
concentration of hydroxy-L-proline between groups reflected a difference attributable to 
age. Age-matched healthy control dogs with histologic confirmation of disease status 
would be needed to more accurately assess the trans-4-hydroxy-L-proline concentrations 
in the control dogs. Therefore, age may have contributed to the finding of a lower serum 
trans-4-hydroxy-L-proline concentration in dogs with mild fibrosis, which may have 
included patients of all ages that may have had occult liver disease, compared with the 
concentration in healthy control dogs.  
 
Furthermore, total urinary hydroxyproline concentration normalized on the basis of the 
urine creatinine concentration was found to be a better indicator of collagen metabolism 
in bone disease than was the serum hydroxyproline concentration [20] To the authors’ 
knowledge, total urinary hydroxyproline concentration has not been evaluated in dogs 
with liver disease and serum proline or trans-4-hydroxy-L-proline concentrations have not 





determine whether lower serum trans-4-hydroxy-L-proline concentrations are a feature of 
dogs with chronic hepatitis, are correlated with the fibrosis score, and can be used as a 
noninvasive biomarker of hepatic fibrosis in this species. A noninvasive biological marker 
of liver fibrosis would not replace histologic examination of a biopsy specimen, but it 
could be used to assess response to therapeutic interventions and as an objective tool for 
prognostic assessment. Additional research is also warranted to determine the importance 
of decreased serum trans-4-hydroxy-L-proline concentrations for collagen metabolism in 







a. Picrosirius Red staining kit, Polysciences, Warrington, Pa. 
b. UltiMate 3000 HPLC, ThermoFisher Scientific, Waltham, Mass. 
c. TSQ Quantiva triple-quadrupole mass spectrometer, ThermoFisher Scientific, 
Waltham, Mass. 
d. TraceFinder software, version 3.3, ThermoFisher Scientific, Waltham, Mass. 
e. Synergi 4 µm fusion–RP, 150 mm X 2 mm, Phenomenex, Torrance, Calif. 
f. TLC, Sigma-Aldrich, St Louis, Mo. 
g. CDN Isotopes, Pointe-Claire, QC, Canada. 
h. Millipore, Milford, Mass. 
i. EMDMillipore, Burlington, Mass. 







1. Lawrence YA, Steiner JM. Canine chronic hepatitis: diagnosis and treatment. 
Today Vet Pract 2015;5(2):26–33.  
 
2. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 
2008;214:199–210. 
 
3. Shih JL, Keating JH, Freeman LM, et al. Chronic hepatitis in Labrador 
Retrievers: clinical presentation and prognostic factors. J Vet Intern Med 
2007;21:33–39. 
 
4.  Sevelius E. Diagnosis and prognosis of chronic hepatitis and cirrhosis in dogs. J 
Small Anim Pract 1995;36:521–528. 
 
5.  Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other 
histologic features, is associated with long-term outcomes of patients with 
nonalcoholic fatty liver disease. Gastroenterology 2015;149:389–397. 
 
6.  Mata JM, Kershenobich D, Villarreal E, et al. Serum free proline and free 
hydroxyproline in patients with chronic liver disease. Gastroenterology 
1975;68:1265–1269.  
 
7. Attallah DAM, Toson EA, Shiha GE, et al. Evaluation of serum procollagen 
aminoterminal propeptide III, laminin, and hydroxyproline as predictors of 
severe fibrosis in patients with chronic hepatitis C. J Immunoassay Immunochem 
2007;28:199–211.  
 
8. Kershenobich D, García-Tsao G, Saldaña SA, et al. Relationship between blood 
lactic acid and serum proline in alcoholic liver cirrhosis. Gastroenterology 
1981;80:1012–1015.  
 
9. Lidbury JA, Hoffmann AR, Ivanek R, et al. Interobserver agreement using 
histological scoring of the canine liver. J Vet Intern Med 2017;31:778–783.  
 
10. US FDA. Guidance for industry: bioanalytical method validation. Washington, 
DC: US Department of Health and Human Services, 2001.  
 
11. Leroy EC, Sjoerdsma A. Clinical significance of a hydroxyproline-containing 
proteins in human plasma. J Clin Invest 1965;44:914–919.  
 
12. Rojkind M, Diaz de León L. Collagen biosynthesis in cirrhotic rat liver slices a 






13. Kershenobich D, Fierro FJ, Rojkind M. The relationship between the free pool of 
proline and collagen content in human liver cirrhosis. J Clin Invest 
1970;49:2246–2249.  
 
14. Chvapil M, Ryan JN. The pool of free proline in acute and chronic liver injury 
and its effect on the synthesis of collagen and globular proteins. Agents Actions 
1973;3:38–44.  
 
15. Toyoki Y, Sasaki M, Narumi S, et al. Semiquantitative evaluation of hepatic 
fibrosis by measuring tissue hydroxyproline. Hepatogastroenterology 
1998;45:2261–2264. 
 
16.      Poole A, Myllyla R, Wagner JC, et al. Collagen biosynthesis enzymes in lung 
tissue and serum of rats with experimental silicosis. Br J Exp Pathol 
1985;66:567–575. 
 
17. Lubec B, Aufricht C, Amann G, et al. Arginine reduces kidney collagen 
accumulation, cross-linking, lipid peroxidation, glycoxidation, kidney weight and 
albuminuria in the diabetic kk mouse. Nephron 1997;75:213–218. 
 
18. Osadchii O, Norton G, Deftereos D, et al. Rat strain-related differences in 
myocardial adrenergic tone and the impact on cardiac fibrosis, adrenergic 
responsiveness and myocardial structure and function. Pharm Res 2007;55:287–
294. 
 
19.  Kim H, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin 
Gastroenterol 2015;31:184–191. 
 
20.       Guanabens A, Pares A, Alvarez L, et al. Collagen-related markers of bone 
turnover reflect the severity of liver fibrosis in patients with primary biliary 
cirrhosis. J Bone Miner Res 2009;13:731–738.  
 
21.  George J, Chandrakasan G. Biochemical abnormalities during the progression of 
hepatic fibrosis induced by dimethylnitrosamine. Clin Biochem 2000; 563-570. 
 
22. Lawrence YA, Rodrigues-Hoffman A, Steiner JM, Shankar S, Klemashevich CL, 
Lidbury JA. Development, validation, and application of a LC-MS/MS method 
for the quantitative determination of trans-4-hydroxy-l-proline in the serum of 









Figure 4.1. Product spectra for LC-MS-MS of trans-4-hydroxy-l-proline (A) and 
trans-4-hydroxy-l-proline-2,5,5-D3 (B). 
Reprinted with permission [22].  
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Figure 4.2. The LC-MS-MS chromatogram for canine serum with endogenous 
trans-4-hydroxy-L-proline (A), canine serum spiked with an internal standard 
(trans-4-hydroxy-L-proline-2,5,5-D3; B), and the summation of both (C). 
Reprinted with permission [22].  
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Figure 4.3. Serum trans-4-hydroxy-L-proline concentrations in 20 dogs with chronic 
hepatitis and 20 heathy control dogs. Each circle represents results for 1 dog, and the 
horizontal line represents the median for the group. *Median value differs 
significantly (P = 0.007) from the median value for the healthy dogs. 









































Figure 4.4. Serum trans-4-hydroxy-l-proline concentrations in 12 dogs with chronic 
hepatitis and mild fibrosis, 8 dogs with chronic hepatitis and marked fibrosis, and 20 
healthy control dogs. *Median value differs significantly (P = 0.02) from the median 
value for the healthy dogs. See Figure 3 for remainder of key. 





















































5. UNTARGETED METABOLOMIC PROFILING OF URINE FROM DOGS WITH 
CHRONIC HEPATIC DISEASE 
 
 Introduction 
Chronic hepatic disease includes idiopathic chronic hepatitis, copper-associated chronic 
hepatitis, drug-associated chronic hepatitis, breed-associated metabolic errors, congenital 
portosystemic vascular anomalies, hepatocellular carcinoma, lobar dissecting hepatitis, 
and granulomatous hepatitis [1]. Differentiating these diseases can pose a diagnostic 
challenge due to the similarities of clinical signs and laboratory findings between different 
diseases. Although an early accurate diagnosis is important for an improved clinical 
outcome, achieving a definitive diagnosis can be cost prohibitive and invasive with the 
histological examination of a liver biopsy specimen regarded as the gold standard. The 
identification of non-invasive biomarkers that can reliably characterize chronic hepatic 
disease is desirable and could have clinical implications.  
 
The liver is a central organ for regulation of metabolism, and a number of metabolic 
disturbances are seen in chronic liver disease patients [2,3]. Data from studies in human 
and animal models have documented alterations in hepatic lipid metabolism, protein 
metabolism, energy metabolism, cytokine metabolism, and increased generation of 
reactive oxygen species in patients with chronic liver disease [4-6]. Global metabolomic 
profiling, the untargeted quantification of small molecules in biologic samples, allows for 
a comprehensive analysis of changes in several metabolic and signaling pathways and 





mass spectrometry to measure low molecular weight metabolites permitting the formation 
of a metabolite profile. Metabolite profiles can be altered by a variety of physiological and 
pathological processes, and therefore global changes in such profiles may signal the 
presence of a particular disease [10,11]. Characteristic metabolite profiles that can 
discriminate between various types of liver disease have been identified in human studies 
[12-17]. There are no previous studies that have evaluated the urine metabolome of dogs 
with chronic hepatic disease to the authors’ knowledge. 
 
The aim of the present study was to compare the urine metabolome of healthy dogs, dogs 
with chronic hepatitis, dogs with hepatocellular carcinoma, and dogs with a congenital 
portosystemic shunt. We hypothesized that there would be a difference in urine 
metabolites between groups and that the four groups would have significantly different 
metabolomes. 
 Materials and methods 
 Patients and procedures 
Adult dogs with definitively diagnosed chronic hepatic diseased diagnosed at Texas A&M 
University Veterinary Medical Teaching Hospital or Gulf Coast Veterinary Specialists 
between January 2011 and December 2014 were enrolled in this prospective observational 
study. The diagnosis of chronic hepatic disease was based on clinical signs, serum 
biochemical evaluation, diagnostic imaging findings, and the histological assessment of a 
liver specimen by a board-certified veterinary pathologist. Liver biopsy specimens were 
collected by diagnostic laparoscopy, where five to eight total specimens were collected 





punch biopsies were collected from one or more liver lobes. The liver biopsy specimens 
were fixed in neutral buffered formalin for routine histological processing. Histological 
sections from formalin-fixed paraffin embedded tissue were stained with hematoxylin and 
eosin. Additional stains were performed at the discretion of the anatomic pathologist and 
attending clinician. Dogs with a suspected congenital portosystemic shunt were evaluated 
by ultrasonography as previously described [18]. Dogs presented for a wellness 
examination to the Small Animal Hospital at Texas A&M University, College Station, 
Texas were used as healthy controls. The health of these dogs was assessed by performing 
a physical examination, owner questionnaire, complete blood count, and a serum 
biochemistry profile. Dogs with clinically important abnormalities were excluded from 
the study. The study was approved by the Texas A&M University Institutional Animal 
Care and Use Committee (Animal Use Protocol #2014-0320). Informed client consent was 
obtained for each dog prior to enrollment in the study.  
 Urine sample collection 
Urine from all dogs was obtained by cystocentesis. Urine samples were at ambient 
temperature for less than 30 minutes before being placed on ice, and then frozen within 1 
hour of sampling for storage at -80°C. Samples collected at Gulf Coast Veterinary 
Specialists were kept at -80°C until shipment on dry ice to Texas A&M University, where 
they were stored at -80°C. All dogs had free access to water; however, food was withheld 






 Urine metabolome analysis 
Untargeted metabolomics analysis was performed by the West Coast Metabolomics 
Center at the University of California (Davis, CA) on a fee-for-service basis. Urine 
aliquots were normalized by urine creatinine concentration measured by a SIRRUS 
Clinical Chemistry Analyzer and extracted by degassed acetonitrile. Internal standards 
C8-C30 fatty acid methyl ethers were added, and the samples were derivatized by 
methoxyamine hydrochloride in pyridine and subsequently by N-methyl-N-
trimethylsilyltrifluoroacetamide for trimethylsilylation of acidic protons. Analytes were 
separated using an Agilent 6890 gas chromatograph (Santa Clara, CA) and mass 
spectrometry was performed on a Leco Pegasus IV time of flight mass spectrometer (St. 
Joseph, MI) following a published protocol [19]. Unnamed peaks were excluded from 
statistical analysis.  
 Statistical analysis 
 Univariate analysis 
Univariate analysis was performed using JMP Pro 13 (JMP Software, SAS Software Inc., 
Marlow, England). The dataset was tested for normality using the Shapiro-Wilk test and 
because it did not meet the assumptions of normal distribution, comparisons between 
healthy dogs, dogs with chronic hepatitis, dogs with hepatocellular carcinoma, and dogs 
with a congenital portosystemic shunt groups were determined using the non-parametric 
Kruskal-Wallis test. The resulting p-values were adjusted for multiple comparisons using 
the Benjamini-Hochberg’s False Discovery Rate and significance was set at q < 0.10 [20]. 
Post hoc testing was performed with Dunn's Test of multiple comparisons using JMP Pro 





 Multivariate analysis 
Data reported as peak height were log transformed prior to multivariate analysis. Principle 
component analysis, random forest analysis, and hierarchical cluster analysis was 
performed using MetaboAnalyst 4.0 (http://www.metaboanalyst.ca) [21]. 
 Results 
 Selection criteria of case and control dogs 
There were 10 healthy control dogs enrolled in the study based on a normal physical 
examination, owner questionnaire, complete blood count, serum biochemistry profile. and 
the absence of any reported clinical signs. There were 10 dogs with chronic hepatitis and 
6 dogs with hepatocellular carcinoma enrolled in the study based on histologic 
examination of a liver biopsy specimen. There were 5 dogs with a congenital 
portosystemic shunt enrolled in the study.  
 Animal population 
The demographics of the healthy control dogs, dogs with chronic hepatitis, dogs with 
hepatocellular carcinoma, and dogs with a congenital portosystemic shunt enrolled into 
the study are summarized in Table 1. Breeds of dogs included in each study group are 
summarized in Table 2. There was a significant difference in the distribution of age and 






Table 5.1. Summary of demographic information of dogs enrolled into the study. 
 
C. Hepatitis – Chronic hepatitis, H. Carcinoma – Hepatocellular carcinoma, Congenital 
PSS – Congenital portosystemic shunt, M – intact or castrated male, F – intact or spayed 
female, groups with same superscript are not significantly different.  
 
Table 5.2. Breed distribution of dogs enrolled into the study. 
 
Group Breed 
Healthy English Setter 
Healthy Golden Retriever 
Healthy Crossbreed Dog 
Healthy Crossbreed Dog 
Healthy Crossbreed Dog 
Healthy English Pointer 
Healthy Standard Schnauzer 
Healthy Crossbreed Dog 
Healthy Boston Terrier 
Healthy Boxer 
Chronic Hepatitis Crossbreed Dog 
Chronic Hepatitis Bassett Hound 
Chronic Hepatitis Labrador Retriever 
Chronic Hepatitis Cirneco Dell'Etna 
Chronic Hepatitis Miniature Schnauzer 
Chronic Hepatitis West Highland White Terrier 
Chronic Hepatitis Crossbreed Dog 
Chronic Hepatitis Labrador Retriever 
Chronic Hepatitis Yorkshire Terrier 
 1 
Heading Control (n = 10) C. Hepatitis (n = 10) H. Carcinoma (n = 6) Congenital PSS (n = 5) p-value  
Age in years (median, range) 4.0, 1-8A 10.8, 2-12 AB   10.5, 5-13B 3.0, 0.5-5 A 0.001 





Table 5.2 Continued 
Group Breed 
Chronic Hepatitis Australian Shepherd Dog 
Hepatocellular Carcinoma Crossbreed Dog 
Hepatocellular Carcinoma Chihuahua Dog 
Hepatocellular Carcinoma Crossbreed Dog 
Hepatocellular Carcinoma Siberian Husky Dog 
Hepatocellular Carcinoma Crossbreed Dog 
Hepatocellular Carcinoma Chihuahua Dog 
Congenital Portosystemic Shunt Pug 
Congenital Portosystemic Shunt Maltese Terrier 
Congenital Portosystemic Shunt Rat Terrier  
Congenital Portosystemic Shunt Miniature Schnauzer 
Congenital Portosystemic Shunt Maltese Terrier 
 
 Differences in the urine metabolome between dogs with chronic hepatitis, 
hepatocellular carcinoma, and a congenital portosystemic shunt 
 
A total of 220 named urine metabolites were identified of which 37 differed significantly 
(p£ 0.05; q<0.10) between healthy control dogs, dogs with chronic hepatitis, dogs with 
hepatocellular carcinoma, and dogs with a congenital portosystemic shunt (Table 3). 
Principle component analysis plots showed a clustering of the enrolled patients based on 
disease classification (Fig. 1). The distribution of the most significant metabolites 
separating the four groups was visualized with a heat map (Fig. 2). Random forest analysis 
identified metabolites that had the highest discriminatory power between the four groups 
(Fig. 3). Urine metabolites involved in glutathione, nitrogen, arginine, and proline 
metabolism and fatty acid biosynthesis that differed significantly between groups were 





Table 5.3. Urine metabolites that differed significantly between healthy control dogs, 
dogs with a congenital portosystemic shunt, dogs with hepatocellular carcinoma, and 
dogs with chronic hepatitis. 
KW – Kruskal-Wallis H Test  
 
Compound Name p-value_KW q-value_KW 
gluconic acid 0.000251 0.021188 
succinic acid 0.000331 0.021188 
glutamine 0.000367 0.021188 
glucose 0.000385 0.021188 
mannose 0.000511 0.022470 
sorbitol 0.000812 0.028368 
glycyl proline 0.000904 0.028368 
valine 0.001032 0.028368 
2-deoxypentitol  0.001229 0.028483 
gluconic acid lactone 0.001321 0.028483 
putrescine 0.001457 0.028483 
cellobiose 0.001554 0.028483 
xylitol 0.002287 0.038710 
3-ureidopropionate 0.003685 0.057910 
tryptophan 0.003995 0.058586 
citric acid 0.005117 0.069541 
adenine 0.005374 0.069541 
ethanolamine 0.005783 0.070113 






Table 5.3 Continued 
 
Compound Name p-value_KW q-value_KW 
3-hydroxybutyric acid 0.006374 0.070113 
heptadecanoic acid 0.007225 0.075687 
palmitic acid 0.009100 0.079666 
glycerol 0.009313 0.079666 
tyrosine 0.009734 0.079666 
lysine 0.010036 0.079666 
 2,5-dihydroxypyrazine 0.010055 0.079666 
2-picolinic acid 0.010088 0.079666 
pyrogallol 0.010139 0.079666 
isomaltose 0.010669 0.080940 
2,3-dihydroxybutanoic acid  0.011770 0.081349 
2-hydroxybutanoic acid 0.012612 0.081349 
ornithine 0.012808 0.081349 
alloxanoic acid 0.013170 0.081349 
2-deoxytetronic acid 0.013342 0.081349 
stearic acid 0.013582 0.081349 
ascorbic acid 0.013668 0.081349 







Figure 5.1. Principal component analysis of the urine metabolome showing clustering 
of samples based on group. The scores plot showed a clustering of groups. CPSS – 







Figure 5.2. Heatmap of the most abundant metabolites in all groups, as identified by 
VIP scores in PLS-DA. Each sample is represented by a single column. The higher 
the intensity of the red color, the higher the abundance of the metabolite (CPSS – 








Figure 5.3. Top 15 metabolites in urine (left panel) in rank order of importance for 
differentiating between dogs with chronic hepatitis, dogs with a congenital 
portosystemic shunt (CPSS), dogs with hepatocellular carcinoma (HCC), and 
healthy control dogs. 
 
Data were generated by random forest analysis. Compounds contributing the most to the 
accuracy of disease classification were identified as those having the highest mean 









Figure 5.4. Urine metabolites of glutathione metabolism with potential value as a 
biomarker of hepatocellular carcinoma, chronic hepatitis, or a congenital 
portosystemic shunt in dogs. 
 
Each metabolite was identified by random forest and/or univariate analysis as important 
for the differentiation of dogs into either control, congenital portosystemic shunt, 
hepatocellular carcinoma, or chronic hepatitis groups. Ornithine was significantly 
different between groups (p = 0.013) and increased in the urine of dogs with hepatocellular 
carcinoma compared to control dogs (q = 0.04). Putrescine was significantly different 
between groups (p = 0.002) and increased in the urine of dogs with chronic hepatitis and 
hepatocellular carcinoma compared to control dogs (q = 0.006, q = 0.01, respectively). 
Ascorbic acid was significantly different between groups (p = 0.14) and increased in the 
urine of dogs with hepatocellular carcinoma compared to dogs with a congenital 










































Figure 5.5. Urine metabolites of nitrogen metabolism, arginine, and proline 
biosynthesis with potential value as a biomarker of hepatocellular carcinoma, 
chronic hepatitis, or a congenital portosystemic shunt in dogs. 
 
Each metabolite was identified by random forest and/or univariate analysis as important 
for the differentiation of dogs into either control, congenital portosystemic shunt, 
hepatocellular carcinoma, or chronic hepatitis groups. Tyrosine was significantly different 
between groups (p = 0.01) and decreased in the urine of dogs with chronic hepatitis 
compared to control dogs (q = 0.01). Glutamine was significantly different between groups 
(p = 0.0004) and increased in the urine of dogs with chronic hepatitis and a congenital 
portosystemic shunt compared to control dogs (q = 0.005, q = 0.0009, respectively). 
Tryptophan was significantly different between groups (p = 0.004) and increased in the 
























































Figure 5.6. Urine metabolites of fatty acid biosynthesis with potential value as a 
biomarker of hepatocellular carcinoma, chronic hepatitis, or a congenital 
portosystemic shunt in dogs. 
 
Each metabolite was identified by univariate analysis as important for the differentiation 
of dogs into either congenital portosystemic shunt, hepatocellular carcinoma, or chronic 
hepatitis groups. Palmic acid was significantly different between groups (p = 0.01) and 
increased in the urine of dogs with chronic hepatitis compared to dogs with hepatocellular 
carcinoma or a congenital portosystemic shunt (q = 0.04, q = 0.03, respectively). Stearic 
acid was significantly different between groups (p = 0.01) and decreased in the urine of 
dogs with a congenital portosystemic shunt compared to dogs with chronic hepatitis (q = 














































This study identified metabolic abnormalities in the urine of dogs diagnosed with chronic 
hepatitis, hepatocellular carcinoma, or a congenital portosystemic shunt with significant 
alterations in 37 of 220 named metabolites. These metabolites are known to be involved 
in a variety of processes, including glutathione metabolism, nitrogen metabolism, arginine 
and proline metabolism, and fatty acid biosynthesis.  
 Abnormal amino acid metabolism and fatty acid biosynthesis 
Significant differences were noted in the relative amounts of metabolites in the urine of 
dogs with chronic hepatitis, hepatocellular carcinoma, or a congenital portosystemic shunt 
compared to healthy control dogs. Among these findings was a significant difference in 
three metabolites derived from glutathione metabolism, ornithine, putrescine, and ascorbic 
acid between groups. Ornithine was significantly increased in the urine of dogs with 
hepatocellular carcinoma compared to healthy control dogs (q = 0.0410). Putrescine was 
significantly increased in the urine of dogs with chronic hepatitis and hepatocellular 
carcinoma compared to healthy control dogs (q = 0.0056, q = 0.010 respectively). 
Ascorbic acid was significantly increased in the urine of dogs with hepatocellular 
carcinoma compared to dogs with a congenital portosystemic shunt (q = 0.02). Glutathione 
(GSH, L-γglutamyl-L-cysteinyl- glycine) is a tripeptide thiol synthesized in all 
mammalian cells [22]. Glutathione detoxifies reactive molecules by either spontaneous 
conjugation or a GSH-S-transferase catalyzed reaction. The liver, kidney, and lungs are 
important sources of GSH; however, systemic concentrations of GSH and its substrates 
are predominantly hepatically derived [23]. Hepatocytes are unique, compared with other 





effluxes into the systemic circulation and bile [23]. The discovery of increased urine 
concentrations of three metabolites derived from glutathione metabolism in dogs with 
chronic hepatitis and hepatocellular carcinoma compared to healthy control dogs and dogs 
with a congenital portosystemic shunt may represented altered glutathione metabolism. 
Decreased quantities of glutathione have been found in the liver of dogs with various liver 
diseases including chronic hepatitis [22]. The increased utilization of the glutathione 
pathway resulting in decreased liver tissue concentrations may result in increased urine 
levels of products derived from glutathione metabolism. There are no previous studies of 
the urine metabolome in dogs with hepatic disease; however, similar findings of increased 
tyrosine, glutamine, ornithine, valine, threonine, and lysine have been reported in the urine 
of humans with Wilson’s disease [24]. 
 
Significant differences in amino acids involved in nitrogen metabolism; tyrosine, 
glutamine, and tryptophan and were detected. There was a significant decrease of tyrosine 
in the urine of dogs with chronic hepatitis compared to healthy control dogs (q = 0.01), a 
significant increase of glutamine in the urine of dogs with chronic hepatitis or a congenital 
portosystemic shunt compared to healthy control dogs (q = 0.0045 and q = 0.0009, 
respectively), and a significant increase of tryptophan in the urine of dogs with chronic 
hepatitis compared to healthy control dogs (q = 0.0016). Glutamine, ornithine, and 
putrescine are also reaction intermediates of arginine and proline metabolism. Most amino 
acids are synthesized and degraded in the liver; thus, injury to the liver can result in 
abnormalities in the metabolism of amino acids and the release of amino acids from 





hepatic disease; however, urine amino acid levels of lysine, valine, threonine, and tyrosine 
are markedly increased in humans with the inflammatory liver disease, nonalcoholic 
steatohepatitis disease are elevated when compared to healthy controls [26]. These results 
of this study are similar to the finding of our study. Alterations in amino acid metabolites 
are thought to represent an adaptive physiological responses to hepatic stress in humans 
with nonalcoholic steatohepatitis and our results may represent a similar response in dogs 
[27].  
 
Additionally, significant differences in two metabolites of fatty acid biosynthesis; palmitic 
and stearic acid were detected. There was a significant decrease of palmitic acid in the 
urine of dogs with hepatocellular carcinoma or a congenital portosystemic shunt compared 
to dogs with chronic hepatitis and a significant decrease of stearic acid in the urine of dogs 
with hepatocellular carcinoma compared to dogs with chronic hepatitis (q = 0.038, 0.026, 
and 0.035 respectively). Long chain free fatty acids (FFAs) can be divided into saturated 
fatty acids, monounsaturated fatty acids, and polyunsaturated fatty acids based on the 
presence of double bonds. The best characterized FFAs in the context of apoptosis are 
palmitic acid, a 16 carbon length saturated fatty acid, oleic acid, an 18 carbon length 
monounsaturated fatty acid, and stearic acid, a 18 carbon length saturated fatty acid [28-
30]. Saturated fatty acids can induce apoptosis in many different cell types and in 
hepatocytes, the saturated fatty acids, palmitic acid, and stearic acid lead to a 
concentration- and time-dependent lipoapoptosis [31]. Thus, the increase in these fatty 





has not been characterized and therefore, the significance of these findings if validated in 
a targeted prospective study is unknown.  
 Potential biomarkers for dogs with chronic hepatitis, hepatocellular 
carcinoma, or a congenital portosystemic shunt  
A subset of compounds in urine were identified for their value in differentiating healthy 
control dogs from those diagnosed with chronic hepatitis, hepatocellular carcinoma, or a 
congenital portosystemic shunt. Random forest analysis identified 15 metabolites that 
were able to classify healthy control dogs (100% accuracy), dogs with chronic hepatitis 
(70% accuracy), dogs with hepatocellular carcinoma (33% accuracy), and dogs with a 
congenital portosystemic shunt (40% accuracy) (Figure 3). Further evaluation of these 
findings in a prospective targeted study is warranted.  
 
Limitations of this study include the influence of concurrent drug administration or diet 
on our findings. The results of this study will need to be validated in a prospective targeted 
study in dogs with chronic hepatitis, hepatocellular carcinoma, or a congenital 
portosystemic shunt. The metabolites in urine can be affected by the cumulative effect of 
complex physiological processes across all tissues in the body, it is not possible to 
definitively determine the organ, cell type, or intracellular compartment from which 
identified compounds originated. Furthermore, the impact of renal excretion versus 
reabsorption, and intestinal microbial metabolism on the types and quantity of compounds 
detected in the urine is unknown. Metabolomic investigation of the serum of dogs with 





to healthy control dogs would provide considerable additional insight into the metabolic 
abnormalities identified in this study and is currently underway. 
 
Untargeted metabolomic profiling of urine from dogs with chronic hepatitis, 
hepatocellular carcinoma, and a congenital portosystemic shunt demonstrated significant 
semi-quantitative differences in 37 of 220 named metabolites, including those involved in 
glutathione, nitrogen, arginine and proline metabolism, and fatty acid biosynthesis. 
Further validation of these results in a targeted study and determination of their utility as 






 References  
1. Poldervaart JH, Favier RP, Penning LC, van den Ingh TSGAM, Rothuizen J. 
Primary hepatitis in dogs: a retrospective review (2002-2006). J Vet Intern 
Med.2009;23: 72–80. doi:10.1111/j.1939-1676.2008.0215.x 
 
2. Charlton MR. Protein metabolism and liver disease. Clin Endocrinol Metab. 
1996;10: 617–635.  
 
3. Kawaguchi T, Yamagishi S, Sata M. Branched-chain amino acids and pigment 
epithelium-derived factor: novel therapeutic agents for hepatitis c virus-
associated insulin resistance. Curr Med Chem. 2009;16: 4843–4857.  
 
4. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic 
disturbances in non-alcoholic fatty liver disease. Clin Sci. 2009;116: 539–564.  
doi:10.1042/CS20080253\ 
 
5. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver 
injury. J Clin Invest. 2004;114: 147–152. doi:10.1172/JCI22422 
 
6. McCullough AJ, Tavill AS. Disordered energy and protein metabolism in liver 
disease. Semin Liver Dis. 1991; 11(4):265-77.   
 
7. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, 
nontargeted ultrahigh performance liquid chromatography/electrospray ionization 
tandem mass spectrometry platform for the identification and relative 
quantification of the small-molecule complement of biological systems. Anal 
Chem. 2009;81: 6656–6667. doi:10.1021/ac901536h 
 
8. Gibney MJ, Walsh M, Brennan L, Roche HM, German B, van Ommen B. 
Metabolomics in human nutrition: opportunities and challenges. Am J Clin Nutr. 
2005;82: 497–503. doi:10.1093/ajcn/82.3.497 
 
9. Hollywood K, Brison DR, Goodacre R. Metabolomics: Current technologies and 
future trends. Proteom. 2006;6: 4716–4723. doi:10.1002/pmic.200600106 
 
10. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer. 
2004;4: 551–561. doi:10.1038/nrc1390 
 
11. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for 
studying drug toxicity and gene function. Nat Rev Drug Discov. 2002;1: 153–
161. doi:10.1038/nrd728 
 
12. Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, et al. 







13. Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K, et al. Serum 
metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination 
among different forms of liver disease. J Hepatol. 2011;55: 896–905. 
doi:10.1016/j.jhep.2011.01.031 
 
14. Kawaguchi T, Izumi N, Charlton MR, Sata M. Branched‐chain amino acids as 
pharmacological nutrients in chronic liver disease. Hepatol. 2011;54: 1063–1070. 
doi:10.1002/hep.24412 
 
15. Zhou L, Wang Q, Yin P, Xing W, Wu Z, Chen S, et al. Serum metabolomics 
reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma 
and chronic liver diseases. Anal Bioanal Chem. 2012;403: 203–213. 
doi:10.1007/s00216-012-5782-4 
 
16. Liu Y, Hong Z, Tan G, Dong X, Yang G, Zhao L, et al. NMR and LC/MS‐based 
global metabolomics to identify serum biomarkers differentiating hepatocellular 
carcinoma from liver cirrhosis. Int J Cancer. 2014;135: 658–668. 
doi:10.1002/ijc.28706 
 
17. Gao R, Cheng J, Fan C, Shi X, Cao Y, Sun B, et al. Serum Metabolomics to 
Identify the Liver Disease-Specific Biomarkers for the progression of hepatitis to 
hepatocellular carcinoma. Sci Rep. 2015;5: 18175. doi:10.1038/srep18175 
 
18. Lamb CR. Ultrasonographic diagnosis of congenital portosystemic shunts in 
dogs: results of a prospective study. Vet Radiol Ultrasound. 1996;37: 281–288. 
doi:10.1111/j.1740-8261.1996.tb01231.x 
 
19. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma 
metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 
2 diabetic obese african-american women. PLoS One. 2010;5: e15234. 
doi:10.1371/journal.pone.0015234 
 
20. Broadhurst DI, Kell DB. Statistical strategies for avoiding false discoveries in 
metabolomics and related experiments. Metabolomics. 2006;2: 171–196. 
doi:10.1007/s11306-006-0037-z 
 
21. Xia J, Wishart DS. Web-based inference of biological patterns, functions and 
pathways from metabolomic data using MetaboAnalyst. Nat Protoc. 2011;6: 
743–760. doi:10.1038/nprot.2011.319 
 
22. Center SA, Warner KL, Erb HN. Liver glutathione concentrations in dogs and 
cats with naturally occurring liver disease. Am J Vet Res. 2002;63: 1187–1197.  
 
23. DeLeve LD, Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity. 






24. Stein WH, Bearn AG, Moore S. The amino acid content of the blood and urine in 
Wilson's disease. J Clin Invest. 1954;33: 410–419. doi:10.1172/JCI102913 
 
25. Munro HN, Fernstrom JD, Wurtman RJ. Insulin, plasma aminoacid imbalance, 
and hepatic coma. Lancet. 1975;1: 722–724.  
 
26. Dong S, Zhan Z-Y, Cao H-Y, Wu C, Bian Y-Q, Li J-Y, et al. Urinary 
metabolomics analysis identifies key biomarkers of different stages of 
nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23: 2771–2784. 
doi:10.3748/wjg.v23.i15.2771 
 
27. Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, et al. 
Branched chain amino acid metabolism profiles in progressive human 
nonalcoholic fatty liver disease. Amino Acids. 2015;47: 603–615. 
doi:10.1007/s00726-014-1894-9 
 
28. de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma 
total and free fatty acids composition in human non-alcoholic steatohepatitis. 
Clin Nutr. 2002;21: 219–223.  
 
29. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A 
lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46: 
1081–1090. doi:10.1002/hep.21763 
 
30. Nehra V, Angulo P, Buchman AL, Lindor KD. Nutritional and metabolic 
considerations in the etiology of nonalcoholic steatohepatitis. Digest Dis Sci. 
2001;46: 2347–2352.  
 
31. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-












Chronic hepatitis is associated with apoptosis, necrosis, and an inflammatory infiltrate that 
is often predominantly mononuclear. Those processes can initiate a repair process that can 
progress to end-stage liver disease characterized by fibrosis of the liver and the 
replacement of normal liver architecture with abnormal liver nodules with portal-central 
vascular anastomoses [2]. End-stage hepatic disease carries a poor long term prognosis 
with a reported median survival time of 0.4 months [3,4]. Chronic hepatitis, in contrast 
diagnosed at an earlier stage carries a reported median survival from diagnosis to death of 
18.3 – 36.4 months [3,4]. Dogs with chronic hepatitis are often diagnosed at an advanced 
stage where treatment is less likely to be effective. Therefore, biological markers are 
needed that can identify dogs with chronic hepatitis, hepatocellular inflammation, or 
hepatic fibrosis, before clinical signs develop.  
 
MicroRNAs (miRNAs) are small non-coding naturally occurring RNAs that regulate gene 
expression by suppressing translation of target messenger RNAs [5,6].  They exert critical 
functions in many physiological processes and are consequently involved in the 
pathogeneses of various diseases. Various miRNAs have been shown to have potential as 
biomarkers for a variety hepatobiliary diseases in humans, including chronic hepatitis C, 
non-alcoholic fatty liver disease, rejection after liver transplantation, drug- or alcohol- 





13]. MicroRNAs are expressed in a number of tissues; however, certain miRNAs are organ 
specific [14]. Hepatic tissue expresses a number of distinct miRNAs that include miR-
122, the single most abundant hepatic miRNA and it is estimated to make up 70% of the 
total hepatically derived miRNA [15]. Because microRNAs are well conserved across 
species and highly stable in blood, they are good candidate biomarkers for liver disease in 
dogs. 
 
The aim of this study was to identify miRNAs that are differentially expressed in hepatic 
tissue from dogs with chronic hepatitis compared to healthy control dogs using Illumina 
small-RNA sequencing. We hypothesized that dogs with chronic hepatitis will exhibit 
differential hepatic miRNA expression compared to healthy control dogs.  
 Materials and methods 
 Animals 
Eight dogs undergoing liver biopsy for routine diagnostic purposes that were subsequently 
histologically confirmed to have chronic hepatitis and 8 healthy control dogs undergoing 
ovariohysterectomy were enrolled at the Texas A&M University Veterinary Medical 
Teaching Hospital between September 2014 and August 2017. Informed client consent 
was obtained for each patient and the study was approved by the Texas A&M University 
Institutional Animal Care and Use Committee (Animal Use Protocols #2014-320 and 
2015-0043). Patients with suspected chronic hepatitis underwent laparoscopic liver biopsy 
and 5 to 8, 5 mm closed cup forceps liver biopsy specimens were collected. The same 5 
mm closed cup forceps were used to collect 3 – 4 liver biopsy specimens from healthy 





0.5 g of liver tissue from each patient was placed in RNAlater (Invitrogen, Carlsbad, CA) 
for a minimum of 12 hours, the RNAlater was then decanted, and the specimen was stored 
at -80°C until further analysis. One liver biopsy specimen was collected in a sterile red top 
tube for copper quantification by atomic adsorption spectroscopy (expressed as µg copper 
per g dry weight) and another was collected and stored in a sterile specimen cup for aerobic 
and anaerobic culture and susceptibility testing. The remaining liver tissue from each dog 
in each group was fixed in neutral buffered formalin for routine histological processing. 
Sections from formalin-fixed paraffin embedded tissues were routinely stained with 
hematoxylin and eosin, picrosirius red, and rhodamine. The diagnosis of chronic hepatitis 
and healthy control were based on clinical signs, routine serum biochemistry panels, and 
histological assessment of liver specimens by a board-certified veterinary pathologist 
according to the World Small Animal Veterinary Association Liver Standardization Group 
Guidelines [16]. The stage of hepatic fibrosis, the grade of necroinflammatory activity, 
and the semiquantitative assessment of copper content were assessed using a previously 
published scoring scheme [2,17]. 
 Total RNA extraction 
Liver tissue stabilized in RNAlater was homogenized with a tissue homogenizer (PRO 
Scientific, Oxford, CT). The extraction of total RNA was performed using the RNeasy 
Plus Mini Kit (QIAGEN, Germantown, MD) according to the manufacturer’s instructions 
and stored at –80°C until analysis. RNA pellets were eluted to sequencing grade water 
(Amresco, Solon, OH), and the quality of total RNA analyzed by the Bioanalyzer Nano 
6000 chip (Agilent Technologies, Santa Clara, CA). Only samples with an RNA Integrity 





 Small RNA library preparation and Illumina sequencing 
Small RNA library preparation for each sample in each group was based on Illumina’s 
TruSeq Small RNA Sample Prep Kit (Illumina, San Diego, CA) following the 
manufacturer’s protocol. Briefly, RNA 3′ and 5′ adapters were ligated to target 
microRNAs in two separate steps. Reverse transcription reaction was conducted to the 
ligation products to create single stranded cDNA. The cDNA was amplified by PCR using 
a common primer and a primer containing the index sequence. Libraries were sequenced 
on an Illumina GA Iix (SCS 2.8 software; Illumina, San Diego, CA), with 50 single end 
sequencing and 2 lanes. Sequence reads were extracted from the image files using the 
GitHub 2.16microRNA profiling pipeline (GitHub Inc. San Francisco, CA, USA). 
 Small RNA sequence and data analysis 
After filtering adaptor sequences and removal of contaminated reads, the clean reads were 
processed for computational analysis. The obtained reads were aligned against the dog 
reference genome (Canis lupus familiaris Boxer genome, NCBI MegaBLAST). 
Subsequently, the sequences were analyzed by a BLAST search against the miRNA 
database, miRBase (version14.0 and 19.0). To prepare for differential miRNA expression 
analysis, miRNAs in the library of each case in both groups were normalized to obtain the 
expression of transcripts per million using the following formula: Normalized expression 
= (Actual miRNA sequencing reads count / Total clean reads count) × 1,000,000. The 
normalized expression values were input into the R/Bioconductor package edgeR [18] for 
differential expression analysis, and rlog transformation was applied as a preprocessing 
step. The edgeR package implements a state-of-the-art- statistical method specifically 





overdispersed Poisson probability regression model was fit to each miRNA, and 
differential expression was assessed via hypothesis testing of the regression model 
coefficients; for testing, we used the edgeR implementation of QL F-tests. To 
accommodate the extreme multiple testing involved in a differential expression analysis, 
raw p-values were translated into q-values (analogs to p-values when the error measure 
used is false discovery rate (FDR) instead of Type I error rate) [19].  
 Results 
 Patient demographics 










Disease Agea Sex Breed FIS  AS HVS CuS Q Liver Cu ALT  ALKP TBILI GGT 
C. Hepatitis  12 SF Labrador Retriever 4 2 1 1 667 466 557 0.2 16 
C. Hepatitis  6 CM
  
Doberman Pincher 3 1 0 2 196 989 283 0.3 12 
C. Hepatitis  9 M Labrador Retriever 2 2 2 0 463 577 230 0.2 <10 
C. Hepatitis  5 M Doberman Pincher 2 2 2 3 3450 750 334 0.2 18 
C. Hepatitis  4 SF  German Shorthaired 1 2 1 2 1080 231 98 0.4 <10 
C. Hepatitis  11 SF Labradoodle 2 2 2 3 1230 663 179 0.3 22 
C. Hepatitis  14 CM
  
Rat Terrier 3 0 3 0 170 476 327 <0.1 12 
C. Hepatitis  9 F Rottweiler Dog 4 1 0 0 257 121 122 0.2 8 
 Control 0.5 F Catahoula Hog Dog 0 0 2  181     
Control 6 F Greyhound Dog 0 0 0  168     
Control 1 F Chihuahua 0 0 0  280     
Control 5 F Staffordshire Terrier 0 0 2  153     
Control 1 F Labrador Retriever  0 0 1  124     
Control 3 F Walker Coonhound 0 0 0  96.3     
Control 0.5 F Labrador Retriever 0 0 0  316     





Table 6.1 Continued  
aAge (years), SF – Spayed female, M – Male, CM – Castrated male, F – Intact female, M – 
Intact male, FIS – Fibrosis score, AS – Activity score, HVS – Hepatocellular vacuolation 
score, CuS – Copper Score, Q Liver Cu – Quantitative liver copper, ALT – Alanine 
transaminotransferase, ALKP – Alkaline phosphatase, GGT – Gamma-glutamyl transferase, 
C. Hepatitis – Chronic hepatitis 
 
 MicroRNA sequencing analysis 
MicroRNAs were evaluated in canine liver tissue from 8 healthy control dogs and 8 dogs 
with chronic hepatitis. There were 50,666,671 and 45,949,375 RNA reads on average per 
sample, respectively that equaled 48,308,023 RNA reads on average per sample. A total 
of 772,928,372 high-quality reads were subjected to analysis. The differential expression 
of hepatic miRNA was evaluated using QL F-test. There were 176 total miRNAs detected 
by sequencing and of these hepatically derived miRNAs, 37 were found to be differentially 
expressed between groups (Table 2) The miRNAs highlighted in gray are liver-specific 
[44-47]. Among the differentially expressed miRNAs, 29 were up-regulated and 8 were 
down-regulated in the liver of dogs with chronic hepatitis compared to the liver of healthy 







Table 6.2. Differentially expressed microRNAs in the liver tissue of dogs with 
chronic hepatitis 
 





MICRORNA EXP. CONTROL (MEAN +/- SD) C. HEPATITIS (MEAN +/- SD) LOGCPM PVALUE FDR 
CFA-LET-7D.MIMAT0034396 Up 40.75+/-2.28 159.87+/-4.73 7.170 0.000 0.011 
CFA-LET-7E.MIMAT0006608 Up 460.17+/-16.5 977.53+/-35.65 9.586 0.005 0.056 
CFA-MIR-1199.MIMAT0031123 Down 0.5+/-0.08 0.07+/-0.01 0.397 0.001 0.017 
CFA-MIR-1296.MIMAT0034413 Up 4.5+/-0.2 9.33+/-0.44 3.167 0.001 0.019 
CFA-MIR-148B.MIMAT0006663 Down 983.92+/-44.97 975.33+/-42 9.675 0.010 0.092 
CFA-MIR-150.MIMAT0006602 Up 47.83+/-2.09 470+/-32.27 8.068 0.004 0.047 
CFA-MIR-15B.MIMAT0006676 Up 59.33+/-3.21 222.33+/-12.66 7.419 0.000 0.003 
CFA-MIR-181A.MIMAT0006707 Up 2853.25+/-101.62 3191.8+/-96.07 11.512 0.000 0.012 
CFA-MIR-1838.MIMAT0006644 Up 2.83+/-0.2 10.8+/-0.58 3.243 0.002 0.039 
CFA-MIR-1840.MIMAT0006679 Up 0.92+/-0.06 5.27+/-0.23 2.323 0.000 0.006 
CFA-MIR-193A.MIMAT0006735 Up 132.67+/-4.91 265.93+/-9.59 7.925 0.002 0.030 
CFA-MIR-193B.MIMAT0006699 Down 23.08+/-0.82 20.93+/-0.73 4.487 0.008 0.088 
CFA-MIR-197.MIMAT0006698 Up 41+/-2.05 125.47+/-5.01 6.763 0.000 0.006 
CFA-MIR-30D.MIMAT0006616 Down 14524.17+/-578.09 12996.53+/-390.08 13.532 0.003 0.045 
CFA-MIR-326.MIMAT0009894 Up 6.17+/-0.21 10.47+/-0.6 3.204 0.000 0.006 
CFA-MIR-328.MIMAT0006688 Up 17.5+/-0.79 39.53+/-1.36 5.180 0.000 0.012 
CFA-MIR-331.MIMAT0009895 Up 28.83+/-1.24 45.2+/-2.66 5.327 0.001 0.019 
CFA-MIR-339-1.MIMAT0011134 Up 249.33+/-15.74 364.47+/-22 8.215 0.002 0.039 
CFA-MIR-350.MIMAT0006704 Up 21.5+/-1.74 28.67+/-2.77 4.392 0.006 0.070 
CFA-MIR-365.MIMAT0001540 Up 917.08+/-51.23 1193.87+/-57.81 10.030 0.002 0.039 
CFA-MIR-423A.MIMAT0006742 Up 743+/-21.41 1623.27+/-42.22 10.477 0.010 0.092 
CFA-MIR-433.MIMAT0006712 Up 0.25+/-0.03 1.13+/-0.11 0.819 0.011 0.100 
CFA-MIR-483.MIMAT0009901 Up 9.25+/-0.55 17.47+/-1.03 3.812 0.010 0.092 






Table 6.2 Continued 
 
* MARKERS HIGHLIGHTED IN GRAY ARE LIVER-SPECIFIC. 
 
  
MICRORNA EXP. CONTROL (MEAN +/- SD) C. HEPATITIS (MEAN +/- SD) LOGCPM PVALUE FDR 
CFA-MIR-504.MIMAT0009907 Up 15.92+/-0.77 60.47+/-2.56 5.828 0.000 0.001 
CFA-MIR-505.MIMAT0009908 Up 12.42+/-0.59 29.6+/-1.13 4.638 0.011 0.100 
CFA-MIR-568.MIMAT0009914 Down 0.33+/-0.06 0+/-0 0.386 0.003 0.045 
CFA-MIR-574.MIMAT0006673 Up 24.75+/-1.35 114.4+/-5.04 6.458 0.001 0.027 
CFA-MIR-8821.MIMAT0034311 Down 0.33+/-0.06 0+/-0 0.298 0.001 0.027 
CFA-MIR-8825.MIMAT0034315 Up 0.08+/-0.02 0.27+/-0.04 0.401 0.001 0.027 
CFA-MIR-8854.MIMAT0034349 Up 0.25+/-0.03 0.4+/-0.05 0.509 0.010 0.092 
CFA-MIR-8859A.MIMAT0034354 Up 293.33+/-10.47 542.8+/-23.64 8.705 0.008 0.088 
CFA-MIR-8881.MIMAT0034381 Up 0+/-0 0.27+/-0.06 0.369 0.003 0.045 
CFA-MIR-8883.MIMAT0034385 Down 0.08+/-0.02 0.07+/-0.01 0.267 0.005 0.057 
CFA-MIR-8887.MIMAT0034391 Down 2.42+/-0.2 1.13+/-0.15 1.441 0.000 0.006 
CFA-MIR-8908B.MIMAT0034415 Up 0.42+/-0.08 0.67+/-0.08 0.665 0.000 0.015 






The microRNA expression profile of liver tissue from dogs with chronic hepatitis was 
compared to the expression profile of liver tissue from healthy control dogs using Illumina 
small-RNA sequencing. After correcting for multiple comparisons, 37 miRNAs were 
found to be significantly differentially expressed: 29 were up-regulated and 8 were down-
regulated (Table 2). This is the first report of miRNA expression profiling of liver tissue 
from dogs with chronic hepatitis to the author’s knowledge.  
 Potential microRNA biomarkers of canine chronic hepatitis  
There are no previous studies of the microRNA profile of liver tissue from dogs with 
chronic hepatitis; however, there are limited studies that characterize the utility of specific 
serum miRNAs in dogs with chronic hepatitis and a study of the microRNA profile of 
liver tissue from Beagle dogs with drug-induced hepatotoxicity [20-22]. Furthermore, 
there are many human studies of microRNA profiling of the liver, serum, and plasma from 
patients with chronic liver disease [23-25].  
 
Fibrosis is the final common outcome of all chronic liver diseases, including chronic 
hepatitis in dogs [26]. Hepatic stellate cells, the matrix‐producing of the liver, once 
activated transform into myofibroblast‐like cells that secrete extracellular matrix leading 
to liver fibrosis [27]. MiRNAs identified in the study presented here that have been 
previously identified as playing a role in hepatic stellate cell activation or hepatic fibrosis 
includes cfa-mir-181a, cfa-mir-150, and cfa-let-7d [28-30]. A study by Brockenhausen et 
al. found that miR‐181a exhibited a direct effect of inducing hepatocyte epithelial–





expression in vivo was increased in liver cirrhosis, similar to the findings of our study 
[29]. MiR-150, another  important suppressor of hepatic stellate cell activation which is 
crucial in the development of liver fibrosis, has been found to inhibit type I and IV collagen 
in activated hepatic stellate cells [31]. Honda et al. demonstrated the anti-fibrotic effect of 
miR-150 in fibroblasts through the regulation of integrin β3, phosphorylated Smad3 and 
COL1A1 expression [32]. Previously, Li et al. found that the expression of miR-150 was 
up-regulated in the serum of human patients with chronic hepatitis B compared with 
control patients [33]. Recently, it has also been shown that the serum level of miR-150 
was able to discriminate mild from severe fibrosis in human patients with 
schistosomiasis[34]. The expression of cfa-mir-150 was increased in the liver tissue of 
dogs with chronic hepatitis; however, confirmation of this finding and serum evaluation 
may be warranted. The let-7 family of miRNAs has been shown to act as a negative 
regulator of hepatic fibrosis in a mouse model via the down-regulation of TβRI [35]. 
Matsuura et al. has also showed that the levels of circulating let-7 family members in 
plasma declined significantly over time during the progression of fibrosis in chronic 
hepatitis C, with an AUC value of 0.776, 0.734 and 0.790 for let-7a, let-7c and let-7d, 
respectively [36]. Similar to these observations, a study by Cai et al. found that let-7d 
(AUC: 0.6270) circulating in serum could discriminate between mild and severe 
schistosomiasis induced hepatic fibrosis [34]. Similarly, the expression of cfa-let-7d was 
increase in liver tissue of dogs with chronic hepatitis in the current study; however, 
confirmation of this finding and serum evaluation is warranted. These findings suggest a 






Aberrant apoptosis is an important feature of chronic liver disease and is associated with 
worsening fibrosis [37,38]. A miRNA identified in the current study previously identified 
as playing a role in apoptosis is cfa-mir-15b, which has been proposed as a non-invasive 
biomarker of chronic liver disease [28,39,40].  Specifically, the administration of miR-
15b and miR-16 was shown to inhibit hepatic stellate cell proliferation and induce 
apoptosis by induction of the mitochondrial-associated anti-apoptosis protein, Bcl-2 in a 
murine model of acute liver failure [40]. The increased expression of cfa-mir-15b in the 
liver tissue of dogs with chronic hepatitis in the current may indicate, if validated a role of 
cfa-mir-15b in canine chronic hepatitis.  
 
There is growing evidence that indicates a role of miRNAs in the modulation of liver 
inflammation through targeting various signaling molecules. A number of miRNAs has 
been implicated in inflammatory responses: miR-155, miR-132, miR-125b, miR-146a, 
miR-150, miR-181, let-7 and miR-21 [41,42] and of these miR-150, miR-181, let-7 were 
altered in the liver of dogs with chronic hepatitis and if validated could indicate a role in 
canine inflammatory liver disease.  
 
There are no previous deep miRNA sequencing studies of serum, plasma, or liver in dogs 
with chronic hepatitis to the authors’ knowledge; however, there have been a number of 
targeted studies of circulating miRNAs (miR-21, miRNA-126, miR-200c, miR-222, miR-
122, miR-29a, miR-148a, miR-181b, miR-133a, miR-17-5) that have been performed in 
dogs with chronic hepatitis [20,21,44].  There were no overlapping transcripts identified 





in canine serum. The circulating miRNAs evaluated in dogs were chosen based on their 
associations with chronic liver disease in humans; however, the serum of dogs with 
chronic hepatitis has not been profiled and it is unknown if the same changes occur. 
MiRNA concentrations in the liver have been found to correlate with serum concentration 
for a number of miRNAs [49,50]. MiRNAs from the liver may enter the serum passively 
through apoptosis and necrosis or actively through secretion of exosomes and viral 
particles [51]. Therefore, although miRNA levels in the serum may estimate miRNA 
activity in the liver it is unknown if the same circulating miRNA profile occurs in human 
and canine liver diseases.  
 
There are a small number of studies that have identified 55 liver specific miRNAs in 
humans  [45-48] of the 300 different miRNAs found in liver tissue [49] and 8 of these 
were differentially expressed in our study (cfa-let-7d, cfa-let-7e, cfa-mir-15b, cfa-mir-
181a, cfa-mir-193a, cfa-mir-193b, cfa-mir-483, cfa-mir-92a).  MiRNA transcripts 
selected for validation should be considered in light of their suspected function and/or 
tissue-specificity. 
 
There are several limitations of this study that should be noted. MiRNAs and their targets 
form complex regulatory networks and a single miRNA can bind to and regulate many 
different mRNA targets and, conversely, several different miRNAs can bind to and 
cooperatively control a single mRNA target [43]. The modulation of any target gene may 
be regulated by the combined efforts of transcription factors, miRNA, protein methylation, 





and the acquisition of a liver biopsy is invasive and limit the examination of miRNAs in 
liver tissue. The evaluation of the identified miRNAs in serum is likely warranted. These 
initial findings due to the probability of a type 1 error should be validated with quantitative 
PCR to confirm these initial findings. 
 
In conclusion, the present study showed the differential expression of hepatic miRNAs 
between dogs with chronic hepatitis and healthy control dogs. The data presented here 
suggested that small-RNA Illumina Sequencing is a powerful approach to study miRNA 
expression profiling. Further investigations are needed to validate these findings and 
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 Application of proteomics in biomarker discovery 
The recent advances in both genomic sequencing and mass spectroscopic technology has 
driven the progress that has been made in the field of proteomics. Proteomics has an 
important role to play in the discovery of disease biomarkers in veterinary medicine and 
this is not limited to canine hepatic disease. The pathogenesis of disease, including chronic 
hepatitis, involves changes in the expression of proteins and this provides the foundation 
for the discovery of candidate protein biomarkers by characterization of the proteome. 
Global analysis of the proteins in a biological sample can identify proteins that can 
improve the diagnosis, staging, prognosis, and treatment monitoring of disease. There are 
a number of protein biomarkers currently utilized in the evaluation of dogs with suspected 
chronic hepatitis (i.e., alanine aminotransferase, aspartate aminotransferase); however, 
deficiencies discovered with the current non-invasive biomarkers include an unacceptable 
frequency of false positives, false negatives, poor sensitivity, and lack of tissue specificity. 
all of which can decrease confidence in the utility of the biomarker. The development of 
more reliable, informative biomarkers or panels of biomarkers for the evaluation of liver 
disease in dogs is needed. The study presented in section 1 identified 11 candidate protein 
biomarkers in the liver tissue of dogs with chronic hepatitis of which two related to 
apoptosis, cytokeratin 18 and annexin 5, were confirmed by western blot analysis.  
Cytokeratins (CKs) represent a multigene family of cytoskeletal proteins that are present 
in large quantities in epithelial cells where they form bundles of intermediate-sized 





cell type-specific patterns that have been identified in humans [5-7]. Two CK subfamilies, 
type I and type II CKs have been distinguished and at least one member of each subfamily 
has to be present for intermediate filament assembly [7]. Among CKs, the pair of CK8 
(type II) and CK18 (type I) is of special interest in liver disease because these two 
polypeptides are the only CKs present in hepatocytes [8]. Furthermore, toxic liver damage 
is drastically enhanced in the absence of CK8 [9].  
 
Reflections and musing: Evaluation of other unconfirmed proteins is important to realize 
the full potential of this study and this technology. Protein molecules with potential based 
on their role in hepatocellular apoptosis would include cytokeratin 8 and annexin A6.  
Furthermore, the analytical validation of existing human diagnostic tests or the 
development of a diagnostic test for the measurement of cytokeratin 18 and annexin 5 in 
canine samples is needed to determine the utility of measurement of these proteins in a 
clinical population. The potential of the proteomic research platform to identify candidate 
biomarkers for chronic hepatitis in dogs is great; however, increasing the resolution for 
separating low abundant proteins and increasing the sensitivity for identifying small 
quantities of proteins would further strengthen this technique. Additionally, the need for a 
well characterized study population cannot be overstated. This is the first study in 
veterinary medicine to utilize the proteomic platform for biomarker discovery in canine 







 Application of metabolomics in biomarker discovery 
The interdisciplinary field of metabolomics combines analytical chemistry, mass 
spectrometry, and sophisticated data analysis to characterize the lipids, sugars, 
nucleotides, amino acids, organic acids and many other low molecular‐weight compounds 
in a biological specimen. These context-dependent metabolites will vary in concentration 
based on the physiology of the cell, tissue, organ or organism. The application of this 
technology to biomarker discovery can assist with the discovery of signals influenced by 
genetics, the environment or their interaction. The value offered by assessment of the 
metabolome resides in the identification of early signals of cellular dysregulation that may 
occur prior to the development of gross disease. Because metabolites represent the 
downstream expression of genome, transcriptome, and proteome, they more closely reflect 
the phenotype of an organism at a specific time and the analysis of metabolic differences 
between unaltered and altered pathways could provide insight into underlying disease 
pathology.  The studies presented in sections 3 – 5 have identified a number of metabolites 
that are altered in the serum or urine of healthy control dogs when compared to dogs with 
chronic hepatitis, hepatocellular carcinoma, or a congenital portosystemic shunt.  
 
Specifically, the ratio of branched chain amino acids to aromatic amino acids was 
decreased in the serum of dogs with a congenital portosystemic shunt. Human patients 
with advanced liver disease demonstrate decreased serum concentrations of branched 
chain amino acids and increased serum concentrations of the aromatic amino acids, 
phenylalanine and tyrosine resulting in a low ratio of branched chain amino acids to 





associated with hepatic encephalopathy and becomes more marked with the progression 
of liver diseases. The ratio has also been used to determine the prognosis of cirrhotic 
patients with or without hepatocellular carcinoma [11,12]. Furthermore, a simplified 
Fischer ratio, the branched chain amino acid to tyrosine ratio, has been reported to be 
useful for predicting serum albumin concentration in human patients with chronic liver 
disease a year from presentation [13].  
 
Reflections and musing: These data indicate that a low Fischer ratio is a marker for 
progression of liver disease in humans, and this should be explored in dogs with chronic 
liver disease.  
 
The fatty acids, palmitic acid and stearic acid were increased in the urine of dogs with 
chronic hepatitis. A recent study in humans with chronic liver disease found a higher 
percentage of palmitic acid, stearic acid, oleic acid, and total monounsaturated fatty acid 
in their red blood cells [14]. Furthermore, palmitic acid red blood cell concentrations were 
identified as an independent predictor of advanced fibrosis [14]. Additionally, research 
suggests that palmitic is the most cytotoxic fatty acid in the liver and can lead to hepatocyte 
injury, apoptosis, and death [15]. Palmitic acid has been also been shown to activate 
hepatic stellate cells, through inflammasomes and hedgehog signaling, leading to the 
progression of hepatic fibrosis [16]. The proportion of stearic acid in red blood cells was 
also significantly increased in patients with advanced fibrosis [14]. Stearic exhibits 
significant cytotoxic properties and contributes to the progression of fibrosis in chronic 





Reflections and musing: Therefore, further evaluation of the metabolic pathways 
involved in fatty acid biosynthesis is warranted in addition to targeted studies to confirm 
these findings. These pathways may become dysregulated early in the course of disease 
prior to gross phenotypic changes and assessment of the complete pathway may allow 
identification of additional disturbances. Furthermore, it is important to investigate not 
only metabolites that are consistent with previously held dogma but to examine novel 
metabolites, such as xylitol that are not well characterized. The tendency to abandon 
metabolites and candidate biomarkers in this stage of discovery may limit development of 
new biomarkers.  
 Application of miRNA expression profiling in biomarker discovery  
The recent introduction of sequencing technology that can perform simultaneous 
sequencing of millions of RNA molecules has made the comprehensive profiling of 
miRNAs possible. The deep sequencing of the small RNA fraction of the transcriptome 
allows researchers to determine miRNA expression and to identify new small RNA 
molecules. MiRNAs are small, non-coding RNAs that regulate post-transcriptional gene 
expression through modification of mRNA stability and suppression of target mRNA 
translation [18]. Due to the tissue specificity of certain miRNAs and their structural 
stability, there is interest in their potential as a novel class of disease biomarker. 
Approximately 60% of mRNAs contain a predicted binding site for miRNA and some 
contain multiple potential binding sites; however, few predicted miRNA–mRNA 
interactions have been validated [18]. A single miRNA is able to regulate multiple genes, 
and conversely a single gene may be regulated by multiple miRNAs [19]. So even a small 





significantly alter the transcriptome [20]. Therefore, unique profiles of miRNA expression 
may potentially be more appropriate to serve as biomarkers for the diagnosis, staging, and 
monitoring of disease and since the gene targets of most miRNAs are unknown, our 
interpretation of changes in expression is markedly limited. The study presented in section 
6 is the first evaluation of the miRNA expression profile of liver tissue in dogs with 
chronic hepatitis. Baseline miRNA levels in hepatocytes and liver tissue have been 
established using deep sequencing methods [21-23]. There are a small number of studies 
that have identified 55 liver specific miRNAs [24-27] of the 300 different miRNAs found 
in liver tissue [28] and 8 of these were differentially expressed in our study (cfa-let-7d, 
cfa-let-7e, cfa-mir-15b, cfa-mir-181a, cfa-mir-193a, cfa-mir-193b, cfa-mir-483, cfa-mir-
92a). While miR-122 accounts for 70% of the total miRNA in the liver other miRNAs 
known to be abundantly expressed in adult human liver tissue, includes miR-16, miR-27b, 
miR-30d, miR-126, as well as the let-7 family of miRNAs [29,30]. Of those cfa-mir-30d 
and cfa-let-7d, and cfa-let-7e were differentially expressed in the presented study. The 
identified differentially expressed miRNAs will require validation in a targeted study 
before determination of diagnostic utility.  
 
Reflections and musing: The miRNA transcripts with the most promise would include 
cfa-mir-150, cfa-mir-181, and cfa-let-7d base on their roles in hepatic inflammation, 
apoptosis, and fibrosis in the human literature. Other miRNA transcripts of interest due to 
their tissue specificity would include cfa-let-7d, cfa-let-7e, cfa-mir-15b, cfa-mir-181a, cfa-
mir-193a, cfa-mir-193b, cfa-mir-483, cfa-mir-92a. The study presented in section 6 has 





specimens from dogs with chronic hepatitis using an Illumina high-throughput deep small 
RNA sequencing platform. The successful application of this technology indicates that 
specific miRNA expression profiles can be identified that could prove to have relevant 
diagnostic, prognostic or predictive clinical value. 
 Summary 
The studies reported here utilized the techniques of untargeted proteomics, untargeted 
metabolomics, targeted metabolomics, and untargeted transcriptomics to investigate 
candidate biomarkers for use in dogs with suspected chronic hepatitis. The findings 
detailed here provide critical targets for new avenues of research. This would include 
biomarker confirmation in targeted studies prior to analytical validation, clinical 
validation, and determination of clinical or diagnostic utility. A significant contribution 
has been made to the discovery of novel biomarkers in dogs with chronic hepatitis. 
Although several challenges exist, the combined results in this dissertation will provide a 
valuable basis for clinical scientists to design studies that analytically and clinically 
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